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AG  aminoguanidine
AGE  advanced glycation endproduct
AGE-R AGE-receptor
AIF  apoptosis-inducing factor
AMP  adenosine monophosphate
AMPK AMP-activated protein kinase
Apaf-1 apoptotic protease activation factor 1
ASK1  apoptosis signal-regulating kinase 1
ATP  adenosine 5’-triphosphate
Bcl-2  B cell lymphoma 2
Bcl-xL  B cell lymphoma-xL
BH  Bcl-2 homology
CaMKII Ca2+/calmodulin-dependent kinase II
CDK  cyclin dependent kinase
CDPK calcium dependent protein kinase
C-t-Ab C-terminus-directed anti-RAGE antibody
C-type constant type
DHAP dihydroxyacetonephosphate
Diablo direct IAP-binding protein with low pI
DNA  deoxyribonucleic acid
DNRAGE dominant negative RAGE
E.C.  enzyme commission
EGF  epidermal growth factor
ERK  extracellular signal-related kinase
G1  gap 1
G2  gap 2
G3P  glyceraldehyde-3-phosphate
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GF  growth factor
GLO1  glyoxalase I
GLO2  glyoxalase II
GLO3  glyoxalase III
Glut  glucose transporter 
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GS  glycogen synthase
GSH  glutathione
GSK-3 glycogen synthase kinase-3
GSNO S-nitrosoglutathione
GTP  guanosine-5’-triphosphate
HK  hexokinase 
HLA-DR human leukocyte antigen-DR
HMGB1 high mobility group box 1
HOG-MAP high osmolarity glycerol-mitogen-activated protein
Hsp  heat-shock protein
HtrA2  high temperature requirement A2
HUVEC human umbilical vein endothelial cell
IAP  inhibitory apoptosis protein
IL-3  interleukin-3
IL-7  interleukin-7
INK4  inhibitors of CDK4
IRS-1  insulin receptor substrate-1
JAK  Janus kinase
JNK  c-Jun N-terminal kinase
M  mitosis
MAPK mitogen-activated protein kinase
MAPKK mitogen-activated protein kinase kinase
MAPKKK mitogen-activated protein kinase kinase kinase
MEK  mitogen extracellular kinase
MG  methylglyoxal
MG-AGEs methylglyoxal-derived advanced glycation endproducts
mTOR mammalian target of rapamycin
NAD  nicotinamide adenine dinucleotide
NADPH nicotinamide adenine dinucleotide phosphate
NF-κB nuclear factor-κB  
NO  nitric oxide
O-GlcNAc O-linked N-acetylglucosamine
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PDGF platelet derived growth factor
PFK  phosphofructokinase
pI  isoelectric point
PI3K  phosphoinositol-3-kinase
PKA  protein kinase A
PKB  protein kinase B
pRb  retinoblastoma protein
PTK  protein-tyrosine kinase
R  restriction point 
RAGE receptor for advanced glycation endproducts 
ROS  reactive oxygen species
rpS6  ribosomal protein S6
S  DNA synthesis
SAPK  stress-activated protein kinase
Smac  second mitochondria-derived activator of caspase
SnRK  SNF1-related protein kinase
SRAGE soluble RAGE
STAT  signal transducer and activator of transcription
TNF  tumor necrosis factor
TP  triosephosphate
TPI  triosephosphate isomerase
VDAC voltage-dependent anion channel
V-type variable type
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Summary
 Whereas for unicellular organisms growth is controlled mainly by the availability 
of nutrients, this does not suffice for multicellular organisms. In multicellular organisms 
nutrients are abundant, so an additional regulatory mechanism is required. This regulatory 
mechanism is provided by the dependence on growth factors (GFs). These GFs are limited 
in the environment of the cells, and competition for GFs between cells determines the 
number, the size and the survival of these cells. Moreover, this competition defines only 
the fittest cells survive, and they survive only in the right place. GFs control several cellular 
processes, including the inhibition of the default apoptotic pathways, the rate of metabolism 
and cell division. Therefore, when GFs are depleted, metabolism collapses, cell division 
ceases and cell death is initiated.
 Results from our group showed that phosphorylation of glyoxalase I (GLO1) is 
involved in tumor necrosis factor (TNF)-induced cell death. Phosphorylated GLO1 is 
directly or indirectly involved in modification of specific target proteins with methylglyoxal 
(MG), an unavoidable by-product of glycolysis. These events are a requisite for TNF-
induced cell death and the data suggested that MG may function as a signaling molecule 
during regulation of cell death.
 In this thesis we describe how GLO1 is phosphorylated upon withdrawal of GFs, 
which leads to a G1 arrest and induction of apoptosis. GF depletion was also accompanied 
by MG-modification of specific target proteins. By pharmacological inhibition we could 
show that both events were GSK-3β-dependent. Inhibition of GSK-3β also significantly 
inhibited apoptosis induced by GF depletion. Next, we determined for which kinase GLO1 
was a direct substrate. It turned out to be not GSK-3β, but by an in vitro kinase assay, we 
found that GLO1 was a direct substrate of Ca2+/calmodulin-dependent kinase II (CaMKII). 
This was later confirmed in cells by coexpression of CaMKII with GLO1.
In addition we found that phosphorylation of GLO1 also occurs during cell division 
by a PI3K-dependent mechanism.
 Given the possibility that effects of MG-modified proteins can be mediated by the 
Receptor for Advanced Glycation End products (RAGE), we subsequently set off a study 
to investigate whether RAGE was regulated during the cell cycle and after GF withdrawal-
induced G1 arrest and apoptosis. We discovered a novel 17 kDa isoform of RAGE. This 
17 kDa RAGE isoform was generated by proteolytic cleavage that could be inhibited by 
the general caspase inhibitor z-VAD-FMK. Processing of RAGE may thus represent an 
additional regulatory mechanism in RAGE signaling. 
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Samenvatting
 Waar bij eencellige organismen de groei voornamelijk bepaald wordt door de 
beschikbaarheid van nutriënten, is dit niet afdoende bij meercellige organismen. Bij 
meercellige organismen zijn nutriënten doorgaans abundant aanwezig in het milieu van 
cellen. Bijgevolg is er een bijkomend regulerend mechanisme vereist. Dit regulerend 
mechanisme wordt voorzien in de afhankelijkheid van groeifactoren (GFs). Deze GFs zijn 
slechts in beperkte mate aanwezig in het milieu van de cel, en de concurrentie voor deze 
GFs bepaalt het aantal, de grootte en de overleving van cellen. Bovendien zorgt deze 
concurrentie ervoor dat enkel de gezondste cellen zullen prolifereren en dat cellen van een 
bepaald type enkel op de juiste plaats zullen overleven. GFs sturen verscheidene cellulaire 
processen, waaronder het verhinderen van de intrinsieke apoptotische signalisatie, het in 
stand houden van het cellulaire metabolisme en het reguleren van de celdeling. Bijgevolg, 
zal, wanneer GFs onttrokken worden, het cellulaire metabolisme vervallen, de celdeling 
stilvallen en celdood in gang worden gezet. 
 Resultaten verworven in onze onderzoeksgroep hebben aangetoond dat fosforylering 
van glyoxalase I (GLO1) betrokken is in tumor necrose factor (TNF)-geïnduceerde 
celdood. Gefosforyleerd GLO1 is vervolgens rechtstreeks of onrechtstreeks betrokken bij 
de modificatie van specifieke doelwitproteïnen met methylglyoxal (MG), een onvermijdbaar 
bijproduct van de glycolyse. Deze gebeurtenissen zijn vereist bij TNF-geïnduceerde 
celdood en de data suggereren dat MG zou functioneren als een signaalmolecule bij de 
regulatie van celdood.
 In deze scriptie beschrijven we hoe GLO1 ook wordt gefosforyleerd tijdens een 
groeistop in de G1 fase van de celcyclus en de hierop volgende apoptose, welke worden 
veroorzaakt door het onttrekken van GFs. Door farmacologische inhibitie konden we 
aantonen dat deze gebeurtenissen afhankelijk waren van GSK-3β. Inhibitie van GSK-3β 
inhibeerde eveneens significant de inductie van apoptose door GF depletie. Vervolgens 
bepaalden we voor welk kinase GLO1 een rechtstreeks substraat vormt. Dit bleek niet 
GSK-3β te zijn, maar door een in vitro kinase assay vonden we dat GLO1 een rechtstreeks 
substraat is van Ca2+/calmodulin-afhankelijk kinase II (CaMKII). Dit werd later in cellen 
bevestigd door co-expressie van CaMKII met GLO1.Daarenboven vonden we dat 
fosforylering van GLO1 ook voorkomt tijdens de celcyclus, en dit op een PI3K-afhankelijke 
wijze.
 Gezien de mogelijkheid dat de effecten van MG-gemodificeerde proteïnen worden 
gemediëerd door de receptor voor gevorderde glycatie eindproducten (RAGE), werd 
vervolgens een aanvang genomen met een studie naar de regulatie van RAGE tijdens de 
celcyclus en bij GF-onttrekking geïnduceerde groeistop in de G1 fase en de daaropvolgende 
apoptose. We ontdekten een nieuwe 17 kDa isovorm van RAGE. Deze 17 kDa RAGE 
isovorm werd opgewekt door proteolytische verknippen,wat verhinderd kon worden door 
de caspase inhibitor z-VAD-FMK. Verknippen van RAGE zou bijgevolg een bijkomend 
regulerend mechanisme kunnen zijn in RAGE signalisatie.
11
Part I:
General Introduction
Part I: General Introduction
12
Chapter 1: The glyoxalase system
13
Chapter 1:  The glyoxalase system
1.1 Introduction
 For almost a hundred years the glyoxalase (GLO) system has been known to exist 
in animals. The discovery dates back to 1913, when two research groups independently 
found enzymes that converted α-oxoaldehydes into corresponding α-hydroxyacids (1,2). 
From then on, research focussed on its putative role in glycolysis. However, when the 
findings of Embden, Meyerhof and colleagues led to the elucidation of the glycolysis (3,4), 
it turned out that the GLO system did not lie on the main route to glucose degradation. 
Thus the hypothesis for a role of the GLO system in glycolysis was abandoned. Later it was 
found that the endproduct of the glyoxalase system was D-lactate and not L-lactate, which 
is the endproduct of glycolysis (5). This was the definite proof that the GLO system was not 
involved in glycolysis and interest in the GLO system severely diminished.
 The ubiquitous nature of the GLO system, nevertheless, suggests a fundamental 
and conserved role (6). In the 1960s Szent-Györgyi took an interest in the GLO system. 
From his research on cancer cells he proposed a role for glyoxalase I (GLO1) in the 
regulation of cell division (7-9). However, until today his hypothesis could not be proven 
since a mechanistic link between GLO1 and the regulation of the cell cycle could not be 
found.
1.2 Detoxification of α-oxoaldehydes
 An important function of the GLO system is the detoxification of reactive α-
oxoaldehydes, mainly methylglyoxal (MG). This reaction is dependent on reduced 
glutathione (GSH) (10) and results in the formation of the corresponding α-hydroxyacid 
(5). 
 The GLO system comprises of two enzymes: glyoxalase I (GLO1; E.C. 4.4.1.5) 
and glyoxalase II (GLO2; E.C. 3.1.2.6). α-oxoaldehydes react nonenzymaticaly with 
reduced GSH, thereby forming a hemithioacetal. GLO1 catalyses the conversion of this 
hemithioacetal to a S-D-hydroxyacylglutathione (11-14), which, in turn, is hydrolyzed to 
the corresponding α-hydroxyacid, hereby regenerating reduced GSH (15) (Figure 1.1). 
The committed step in this pathway is the reaction catalysed by GLO1 since, under 
physiological conditions, it is considered irreversible (13).
 The GLO system has a broad substrate specificity for α-oxoaldehydes (16-18), but 
the reaction rates are inversely correlated to the hydrophobicity of the side chains of the 
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substrate (19). MG is generally considered to be the primary physiological substrate for the 
glyoxalase system. Under physiological conditions the GLO system reaction rates for the 
catalysis of MG are near diffusion-controlled limits (20-22), making the GLO system very 
efficient, and keeping the intracellular levels of MG low. The efficiency of the detoxification 
of MG is primarily determined by the spontaneous formation of the hemithioacetal. In 
aqueous solutions at pH 7, MG appears in α-oxoaldehyde, but also in a mono- and 
dehydrated form. When physiological concentrations of GSH are present, the equilibrium 
is shifted towards the formation of the hemithioacetal, and MG is efficiently removed by the 
GLO system (23,24) (see also chapter 2: Methylglyoxal).
1.3 Glyoxalase I
 As previously mentioned the first step in the detoxification process by the glyoxalase 
system is the conversion of the hemithioacetal, which is spontaneously formed by MG 
and GSH, into S-D-lactoylglutathione. This reaction is catalysed by GLO1 (Figure 1.2). 
The cristal structure of GLO1 shows that the active site is situated in a barrel which is only 
formed at the dimer interface (25). This active site comprises a Zn2+ ion interacting with 
side chains from both subunits. The side chains involved are Glu33 and Glu99 from one 
subunit and His126 and Glu172 from the other. The structure of the active site suggests the 
mechanism is a proton transfer between the C-1 and C-2 of the hemithioacetal, whereby 
the ene-diol intermediate is stabilized in the cis configuration with both oxygens orientated 
towards the Zn2+ ion (25-28). The intermediate is rapidly ketonized to the hemithioacetal. 
It has been proposed that Glu172 and Glu99 are the catalytic bases for the S-substrate and 
R-substrate respectively (29-31).
 GLO1 has been described to exist in various organisms, going from prokaryotes 
over yeast to plants, mammals and humans (e.g. (11,20,32-42)). In mammals and higher 
eukaryotes GLO1 functions as a dimeric metalloenzym, using Zn2+ as a cofactor (see 
Figure 1.1. The glyoxalase system.
The GLO system comprises of 2 enzymes, GLO1 and GLO2. α-oxoaldehydes spontaneously 
react with GSH to form a hemithioacetal, which is converted to a S-D-hydroxyacylglutathione 
by GLO1. This S-D-hydroxyacylglutathione is subsequently hydrolized to the corresponding α-
hydroxyacid, hereby regenerating reduced GSH. (R = CH3 for MG).
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above). GLO1 from Escherichia coli, however, needs Ni2+ for its activation (36). In yeast 
GLO1 functions as a monomer and contains two active sites (43). Monomeric human 
GLO1 is a protein of 184 amino acids with a molecular mass of approximately 21 kDa. It 
has 51% homology at the nucleotide level and 42% homology at the amino acid level with 
bacterial GLO1 (44). The GLO1 dimer is extremely stable and shows a high resistance to 
reducing conditions (45). GLO1 is present in a concentration of approximately 0,2 µg/mg 
protein in most human tissue (46). 
 The human GLO1 gene is located at chromosome 6 (47) and its locus is linked 
to the HLA-DR (human leukocyte antigen-DR) (48,49). The gene for GLO1 was first 
described as one with five exons (45,50), but recent analysis indicates that it contains 
six exons (51). Human GLO1 is expressed from an autosomal diallelic gene and thus is 
expressed in three different phenotypes, GLO1 1-1, GLO1 2-2 and GLO1 1-2, representing 
the two homozygous and heterozygous expression patterns that are characteristic for co-
dominant expression (52). GLO1 1-1 is electrophoretically slower than GLO1 2-2 (53). 
The difference in the two alleles is a single nucleotide polymorphism, resulting in an amino 
Figure 1.2. Proposed catalytic mechanism for glyoxalase I.
The active site of GLO1 is situated at the dimer interface and contains a Zn2+ ion which interacts with side 
chains from both monomers (designated A and B). The substrate is the R-hemithioacetal and Glu99 initiates 
the reaction as catalytic base. See text for more details (Adaptation from (27,30)).
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acid substitution at position 111 from an alanine to a glutamic acid, thereby changing the 
electrophoretic properties (54). This variation also results in a decrease in glyoxalase 
activity (55). Several nucleotide polymorphisms have been described in the 5’ and 3’ 
untranslated regions and these polymorphisms may affect GLO1 expression, stability or 
posttranslational regulation. This may also affect the function of GLO1 (51). It has been 
claimed that some GLO1 phenotypes show correlation with diseases such as autism (55), 
multiple sclerosis (56), diabetes (57-59) and prostate cancer (60).
1.4 Posttranslational modification of glyoxalase I
 There are several reports on posttranslational modification of GLO1. Studies in 
plants, yeast and mammals show that GLO1 is subject to phosphorylation and responds 
to nitric oxide (NO), indicating that posttranslational modification is conserved and is 
important for its biological function.
 Phosphorylation: phosphorylation has been described to occur in mammalian 
cells, in yeast and in plants. Phosphorylation of GLO1 in mammalian L929 cells has been 
described as a necessity for the induction of necrosis by tumor necrosis factor (TNF) (61). 
This phosphorylation doesn’t alter the detoxification capacity of the glyoxalase system for 
MG.
 In yeast, treatment of the α-type budding strain of Saccharomyces cerevisiae with 
mating factor also induces phosphorylation of GLO1 (62). In contrast to the phosphorylation 
in mammalian cells, in yeast the activity of GLO1 was enhanced (63).
 In Arabidopsis, GLO1 was phosphorylated upon the over expression of the kinase 
SnRK2.8, a kinase involved in resistance to stress (64). Concomitantly, a rise in GLO1 
activity was induced. In rice leafs, gibberellin, a regulator of growth, induces phosphorylation 
of GLO1 (65), albeit this is a novel type of plant GLO1 (41). Possible changes in GLO1 
activity were not reported.
 Response to NO: research in yeast and mammalian cells indicates that GLO1 
is responsive to NO. In mammalian endothelial cells the addition of NO leads to the 
inactivation of GLO1 (66). The addition of NO also leads to an increase of the isoelectric 
point (pI) of GLO1. The effects induced by NO on GLO1 are dependent on the formation 
of S-nitrosoglutathione (GSNO), suggesting that the substrate recognition site of GLO1 
is most likely involved (67). Later it was shown that at least three cystein residues were 
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sensitive to NO-induced modification (68). Also in yeast and in vitro the addition of GSNO 
inhibits the activity of GLO1 (69).
 Interplay between phosphorylation and NO has also been shown. In the TNF-induced 
necrosis in L929 cells NO-induced modification and phosphorylation occur independently. 
The NO-mediated modification is not required for the TNF-induced phosphorylation, 
although TNF-induced phosphorylation does primarily occur on the NO-responsive form of 
GLO1 (68).
1.5 Glyoxalase II
 The second step in the detoxification of α-oxoaldehydes is the hydrolysis of the S-
D-hydroxyacylglutathione formed in the first step (see above) to an α-hydroxyacid, hereby 
regenerating reduced GSH. Although GLO2 is a very efficient enzyme for the hydrolysis of 
S-D-lactoylglutathione (70), which is considered its physiological and preferred substrate, 
it is considered to be the rate limiting enzyme of the glyoxalase system (71). GLO2 is a 
monomer, consisting of two domains. The active site extends over the domain interface 
and contains a binuclear Zn-binding site. The active site also contains a water molecule, 
presumably in the form of a hydroxide ion. This hydroxide ion probably acts as the 
nucleophile catalysing the hydrolysis (72), whereby the Tyr175 residue contributes to the 
binding of the GSH derivative (73).
 Like GLO1, GLO2 has been described in various organisms, from prokaryotes over 
plants to mammals (74-82). GLO2 exists as multiple isozymes and has been located not 
only in the cytosol, but also in mitochondria. The human gene for GLO2 has been assigned 
to chromosome 16 (83) and some polymorphism has been described (84). 
 In mammals, the GLO2 gene gives rise to two distinct mRNA species transcribed 
from 9 and 10 exons respectively. The former of the two encodes for two protein species, 
mitochondrial targeted GLO2 and cytosolic GLO2, both initiated from different AUG codons. 
The latter mRNA species only encodes for cytosolic GLO2 (85). The mitochondrial GLO2 is 
located in the matrix and intermembrane space (86).
 In plants and yeasts however, cytosolic and mitochondrial GLO2 are encoded by 
different genes (76,87). Multiple forms of mitochondrial GLO2 exist in plants and GLO2 
can be located in the matrix and in the intermembrane space (86). Some mitochondrial 
isozymes have a Fe³+Zn2+ metal center instead of the two Zn2+ ions described for human 
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GLO2 (88). In Arabidopsis thaliana the different GLO2 isozymes are differently expressed 
in plants, with cytosolic GLO2 being more abundant in flower buds and mitochondrial 
GLO2 being more abundant in roots (76).
 Quite interesting is the fact that GLO2 appears to be regulated by members of 
the p53 family of proteins. In the temporal cortex of p53-/- mice GLO2 is decreased (89). 
Xu and Chen report that GLO2 is up-regulated by p63 and p73, two members of the p53 
family that have fundamental roles in development (90). They postulate that GLO2 serves 
as a pro-survival factor and plays a critical role in the normal development and in the 
pathogenesis of various human diseases (e.g. cancer and diabetes).
1.6 Glyoxalase III
 In Escherichia coli, the existence of a novel GLO enzyme, glyoxalase III (GLO3), 
has been described, which catalyses the conversion of MG to D-lactate (91). GLO3 works 
independently of the other two glyoxalases and in contrast to GLO1 and GLO2, does not 
require GSH as a co-factor. Specificity of this enzyme is limited to MG and phenylglyoxal. 
GLO3 is inactivated by oxidative stress (92). Besides the fact that GLO3 seems to play a 
role in the survival of non-growing Escherichia coli cultures (93), not much is known about 
this enzyme.
1.7 Possible functions of the glyoxalase system
 
 It is quite obvious that the detoxification of α-oxoaldehydes, MG in particular, is 
a very important function for the glyoxalase system. However, the complex nature of 
the glyoxalase system (e.g. the fact that it comprises two enzymes, and not just one), 
the ubiquitous and conserved nature of the glyoxalase system, the existence of several 
other detoxification mechanisms for MG (see also the chapter 2: Methylglyoxal) and the 
existence of MG synthases in eukaryotes and prokaryotes (94-97) suggest that there are 
other, perhaps more fundamental functions for the glyoxalase system. Moreover, because 
of the different levels of regulation and modification of the different enzymes it is unlikely 
that the only role for the glyoxalase system is detoxification of MG. Two possible functions 
that will be emphasised here are an involvement in cell division and a role during stress.
 A possible function in cell division: In plants it was observed that there was 
a strong correlation between GLO1 activity and cell proliferation (98,99). The observation 
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was made that in strongly dividing parts of the plant the concentration of MG was low and 
the GLO1 activity was high. In non-dividing parts, the level of MG was higher and GLO1 
activity was undetectable. Also, when the cell cycle was inhibited, a decrease in GLO1 
activity was induced and when GLO1 was inhibited, a significant inhibition of the increase 
in cell number and DNA content were observed. When soybean cell suspensions or carrot 
cell suspensions were treated with auxin, the activity of GLO1 was modulated together with 
proliferation (100,101). Gibberellin, another important growth regulator in plants, induces 
phosphorylation of GLO1 (65). 
 In yeast GLO1 activity correlates with the overall growth status, although it is not 
involved in the regulation of cell cycle (102). Furthermore GLO1 activity alters and is 
phosphorylated after treatment with mating factor (62,63). Mating factors are known to 
induce G1 arrest in haploid yeast cells (103,104).
 In addition, in animals a correlation between cell proliferation and activity of the 
glyoxalase system was found. Principato et al. found that GLO1 activity was high in 
embryonic chicken tissue, and GLO2 activity was low. This relation was inversed in mature 
chicken tissues, where a low GLO1 activity and a high GLO2 activity were observed (105). 
Also, in regenerating liver after partial hepatectomy, high GLO1 activity and low GLO2 
activity were found. These activities returned to control levels after regeneration (106). 
During the maturation of human erythrocytes it was found that GLO1 activity increased, 
but a decreased activity of GLO1 was seen in mature, old erythrocytes (107). A very 
strong correlation was also found in the development of Bufo bufo embryos. Already at the 
earliest stages of development significant levels of GLO1 activity could be measured, and 
GLO1 activity rose during development. GLO1 to GLO2 activity ratios are very high at the 
beginning of development and gradually decrease as the development progresses (108). 
When differentiation is induced in HL-60 and K526, both leukaemia cell lines, a concomitant 
decrease in GLO1 to GLO2 activity ratios is seen (71). High expression levels of GLO1 
are considered a risk factor for the development of certain types of cancer, and numerous 
tumours show a significant increase in levels and activity of GLO1 and a high GLO1 to 
GLO2 activity ratio in comparison to corresponding non-tumour tissues and surrounding 
tissues (109-117). Albert Szent-Györgyi was a strong believer in a very fundamental role 
for GLO1 and its substrate MG in the regulation of cell division and built his ‘promine/retine’ 
theory around it (e.g.(7-9,118,119) reviewed in (120)). However, in general the glyoxalase 
system is considered to be a ‘marker for cell growth and division’, but a causal relationship 
between the glyoxalase system and cell growth remains obscure.
 A possible function in stress tolerance: A firm link between expression levels and 
activity of GLO1 and the resistance to abiotic stress has been established in plants. In 
Brassica juncea it was found that GLO1 was upregulated in response to salt, water and 
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heavy metal stresses (40). Moreover, in tomato plants an induction of GLO1 and GLO2 was 
observed in response to several forms of stress (121). Transgenic plants over-expressing 
GLO1 also showed an increase in tolerance towards salt and MG. Research in several 
plant species showed that in response to salinity, cold and drought, MG concentrations 
in the plant increase, which results in the inhibition of seed germination. This effect was 
enhanced by the down-regulation of GLO1 (122). Over-expressing components of the 
glyoxalase system led to enhanced tolerance towards salinity or heavy metal stress in 
several plant species (123-126). Furthermore it was observed that overexpression of 
SnRK2.8, a kinase involved in resistance to several types of stress in plants, induces 
phosphorylation of GLO1 (64). 
 In yeast, osmotic stress leads to alteration in GLO1 levels or activity. Inoue and co-
workers reported the induction of GLO1 gene expression in Saccharomyces cerevisiae 
in response to osmotic stress (127). GLO1 activity is regulated in Schizosaccharomyces 
pombe in response to osmotic stress, as well. No change in mRNA levels or protein levels 
was observed in this case, so the effect was induced by posttranslational modification of 
GLO1 (128). In Candida albicans the regulation of GLO1 by the transcription factor Cap1p 
is part of the stress response induced by oxidative stress (129).
 In animals, as well, the GLO1 is involved in resistance to different kinds of stress. 
Expression of GLO1 is up-regulated in the parasitic nematode Onchocerca volvulus under 
conditions of oxidative stress (37). Miller et al. showed that GLO1 provides protection of 
human retinal pericytes against hyperglycemia-induced cell death (130). Overexpression 
of GLO1 in bovine endothelial cells protected against the effects of hyperglycemia (131). 
It has been reported that tumors with high levels of GLO1 are more resistant  to antitumor 
induced-apoptosis (132). Therefore a lot of effort has been put into finding inhibitors for 
GLO1 to be used as antitumor agents (e.g. (133-136)).
 Regulation of the glyoxalase system may be a requirement for organisms to meet 
altered metabolic demands imposed by stress.  In a sense, cell division can be regarded 
as a form of stress and the regulation of the glyoxalase system may be a consequence of 
adaptation to that stress. Indications of this, are, for instance, the involvement of similar 
signaling pathways that are involved in both stress response and cell division (e.g. Ca2+ 
(136,137) and MAPK pathways (127)).
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Chapter 2:  Methylglyoxal
2.1 Introduction
 Methylglyoxal (2-oxopropanal, MG) has long been thought of simply as a by-
product of glycolysis, which is the most fundamental metabolic pathway. Recent research, 
however indicates that there might be more to this molecule than just a role as cytotoxic 
by-product. 
 MG is a reactive dicarbonyl compound known to form covalent adducts with proteins 
and nucleic acids (138). In aqueous solutions it is present in three forms, the unhydrated, 
monohydrate and dihydrate forms, which are in equilibrium. The presence of physiological 
concentrations of glutathione (GSH) shifts this equilibrium towards the formation of the 
hemithioacetal, and MG is efficiently removed by the glyoxalase system (Figure 2.1) 
(23,24,139).  
Figure 2.1. Methylglyoxal in aqueous solutions.
 The main sources of MG are triose-phosphate (TP) glycolytic intermediates. Non-
enzymatic fragmentation and elimination of phosphate from glyceraldehyde-3-phosphate 
(G3P) and dihydroxyacetonephosphate (DHAP) (140,141) or leakage of phosphor-ene-
diolaat from the active site of triosephosphate isomerase (TPI) (142,143) contribute most 
to the formation of MG (Figure 2.2). Metabolism of acetone and threonine also ads to the 
formation of MG (144-146), but under normal metabolic conditions both the latter pathways 
can be considered to be of minor importance. MG can also be formed enzymatically by 
methylglyoxal synthases (94-97,147-149), although the importance of these enzymes has 
not been further investigated in higher eukaryotes and therefore remains obscure.
 An important regulator of intracellular MG levels is the glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Reduced activity of GAPDH leads to the accumulation of TPs, 
leading to a subsequent increase in MG formation (150). GAPDH activity is influenced by 
e.g. oxidative stress (151) and by MG modification (152). This suggests that MG is able to 
propagate its own formation.
 Cells contain considerable amounts of MG. The majority of the MG present in vivo 
however, is bound to proteins (see also below). Chaplen and colleagues detected up to 
310 µM of MG in chinese hamster ovary cells and estimate that 5-10% of cellular proteins 
may be modified to physiologically significant levels (153).
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Figure 2.2. Main metabolic origins of methylglyoxal in mammalian cells.
MG is mainly formed by non-enzymatic or enzymatic elimination of phosphate 
from triose-phosphate intermediates from glycolysis. Also acetone and 
threonine metabolism contributes to MG formation in mammalian cells, albeit 
considerably less. 
2.2 Modification of proteins
 MG is able to modify proteins under physiological conditions (154). The reactions 
proceed even at physiological concentrations of MG and lead to the reversible and 
irreversible modification of arginine and lysine residues and to the reversible modification 
of cysteine residues (Figure 2.3). However, when compared to cysteine residues, there is a 
clear preference for arginine and lysine residues to be modified (155). Although from model 
studies with Nα-acetylamino acids the reaction of MG with protein is expected to be the most 
rapid at cysteine residues, in vivo MG-modified cysteines have not yet been detected, most 
likely because of their unstable and reversible nature (154). The modification of cysteine 
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with MG yields a hemithioacetal (156) (Figure 2.3.A). An example of such a reaction would 
be the reversible and non-enzymatic reaction between MG and GSH. 
 Under physiological conditions the primary targets are the arginine residues (157). 
A major physiological glycation adduct formed from MG with arginine is the imidazolone 
Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (Figure 2.3.B) (158,159).
Figure 2.3. The reaction of methylglyoxal with cysteine and arginine residues.
A.  Reaction of MG with a cysteine residue (e.g. glutathione). B. Reaction of MG with an arginine residue. R 
= peptide chain.
 Further irreversible reactions of the MG-modified arginine and lysine residues 
lead to the formation of Advanced Glycation Endproducts (AGEs). This reaction is slow 
and is called the maillard reaction. Formation of these AGEs is often accompanied by 
oxidative stress and leads to the dysfunctioning of protein and cells. AGEs contribute to the 
development of numerous pathophysiological conditions, such as diabetes, Alzheimer’s 
disease and atherosclerosis, and aging (for reviews see (158,160-164)).
 Glycation of a protein by MG generally induces partial unfolding; this renders 
proteins instable and induces degradation. MG modification, therefore, might function as a 
signal for the degradation of protein (154,157).
 Interestingly, MG modification displays a high specificity. MG modification is 
restricted to preferential proteins (165-167), as well as to specific residues of these target 
proteins (168-170).
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2.3 Detoxification of methylglyoxal
 Besides the glyoxalase system (see chapter 1: The glyoxalase system) several 
other pathways contribute to the detoxification of MG. 
1. Aldose reductase is dependent on NADPH and catalyses reduction of a wide range 
of aldehydes; MG is reduced to acetol, or when MG forms the hemithioacetal with GSH, to 
lactaldehyde. Both can then be reduced to propanediol, also catalyzed by aldose reductase 
(171-173).
2. Betaine aldehyde dehydrogenase is NAD-dependent and oxidizes numerous 
aldehydes, among which, MG. The efficiency of MG oxidation is considerably low in 
comparison with betaine aldehyde, its physiological substrate (174).
3. 2-oxoaldehyde dehydrogenase catalyses the NADP-dependent oxidation of MG to 
pyruvate. This enzyme seems primarily of importance in the liver, but has been purified 
from erythrocytes, as well (175-178). 
 However, under normal physiological conditions the glyoxalase system is the most 
important pathway for MG detoxification (24,127,171,179). Expression and activity of the 
glyoxalase system decrease with age, leading to a rise in MG and, consequently, AGE 
formation (165-167,180,181).
2.4 Methylglyoxal as a cytostatic and cytotoxic molecule
 Ever since Szent-Györgyi hypothesized a function of MG as a regulator of cell 
division ((7-9,118), reviewed in (120)), a lot of attention has been given to this proposed 
role of MG.
 
 MG exerts its activity on proliferation and survival in different ways:
1. MG signals are mediated by receptors (see chapter on RAGE)
2. MG and S-D-lactoylglutathione, an intermediate in the detoxification of MG, are 
capable of inhibiting DNA-synthesis and inducing DNA-damage, leading to G1 arrest and 
subsequently to apoptosis (182-189).
3. Reactive oxygen species (ROS) are generated during the reaction of MG with amino 
acid residues (190-193). Cell lines that are more sensitive to oxidative stress are therefore 
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also more sensitive to the effects of MG (194,195). A first effect of high concentrations of 
ROS and MG is a depletion of cellular GSH, hereby impairing protection against oxidative 
stress and detoxification in general (194,196-199). Superoxide formation also leads to the 
activation of p38 MAPK and JNK, signaling cascades leading to apoptosis (195,200-202) 
(see also paragraph ‘MG as a signaling molecule’).
4. In human embryonic kidney cells (HEK293) and a mouse fibroblast cell line 
(NIH3T3) MG has been shown to render these cells resistant to the mitogenic action 
of insulin-like growth factor-1 (IGF-1). This effect was associated with a stronger and 
prolonged activation of ERK (extracellular signal-related kinase) and an up-regulation of 
p21 (Waf1/Cip1) (203).
5. The impairment of insulin signaling by MG is well documented. MG reacts with 
insulin, hereby changing the biological functions of insulin (204). In addition, downstream 
effector proteins of the insulin receptor are modified, impinging on insulin signaling (205). 
Other receptors, such as the platelet derived growth factor (PDGF) receptor and epidermal 
growth factor (EGF) receptor, are also inhibited in their signaling by MG (206-208).
6. Glycolysis and mitochondrial respiration are sensitive to MG. Tumor cells seem 
particularly sensitive to these inhibitory effects (209-215). This inhibition is mainly the 
consequence of inactivation of GAPDH, but also of hexokinase (HK). At the mitochondrial 
level, the inhibition occurs at complex I of the respiratory electron transport chain.
7. The covalent modification of proteins by MG plays a role in cell survival, as well. Two 
examples are the modification of heat-shock protein 27 (Hsp27) (169,216-219) and of the 
mitochondrial permeability transition pore (220,221). In both cases MG reversibly modifies 
arginine residues, hereby influencing the structure and function of the involved protein. 
These MG modifications protect cells against apoptotic stimuli, somewhat in contrast to the 
other examples, where MG induces cell cycle arrest in the G1 phase or apoptosis.
2.5 Methylglyoxal in other signaling pathways
 Despite its evident cytostatic and cytotoxic properties, MG is inevitably present in 
every cell under physiological conditions, from prokaryotes to higher eukaryotes. Not only 
is it a by-product of glycolysis, the most fundamental metabolic pathway, several other 
metabolic pathways lead to the formation of MG in microorganisms and higher eukaryotes, 
as well. These facts, together with the well-documented existence of prokaryotic as well 
as eukaryotic MG synthases, make the explanation of MG as a mere flaw of metabolism 
unsatisfying. Recent reports suggest a possible role for MG as a signaling molecule.
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 In plants: Under stress conditions a rise in intracellular MG concentration has 
been observed (122). This seems to be a general mechanism, as a rise of intracellular MG 
concentrations has been measured in several different plant systems. This suggests that 
MG, therefore, could act as a signal for plants to respond to stress.
 In yeast: In Saccharomyces cerevisiae it has been shown that the activity of 
Yap1, a transcription factor that mediates the oxidative stress response, is modulated 
by methylglyoxal (222). The localisation of Yap1 in the cytoplasm or the nucleus is 
influenced by intracellular concentrations of MG. Yap1 is most likely directly modified by 
MG, presumably on a cysteine residue. This modification is reversible and independent of 
ROS formation in the cell. It has also been reported that extracellular MG activates several 
signal transduction pathways, like the high osmolarity glycerol (HOG)-mitogen-activated 
protein (MAP) kinase pathway, hereby eliciting the induction of several genes (223,224). In 
addition, MG transiently activates the uptake of Ca2+ from the medium (224). Both responses 
are independent of ROS formation, neither are they caused by changes in osmolarity due 
to the higher concentration of extracellular MG. Maeta and colleagues hypothesize there 
might exist a sensory system for external MG on the cell surface conveying signals to the 
nucleus. A likely candidate for this is the osmosensor Sln1. 
 In Schizosaccharomyces pombe an alternative mechanism has been shown to exist. 
Here extracellular MG activated a yeast homologue of the stress-activated protein kinase 
(SAPK) pathway, leading to activation of the transcription factor Spc1 and independent of 
this Spc1-SAPK pathway Pap1, a Yap1 homologue in S. pombe, is activated, as well (170). 
The activation of Spc1 through the SAPK pathway takes place irrespective of intracellular 
MG content. Activation of Pap1, on the other hand, is reversible and dependent on 
intracellular MG. ROS are not involved in either of the pathways. MG could, therefore, 
be a metabolic signaling molecule. Intracellular levels of MG vary depending on growth 
conditions and stress situations. These alterations in MG concentrations could then elicit a 
response through the modification of different signaling molecules (225,226).
 In mammals: In mammalian cells the pathways involved in the mediation 
of MG-induced signals and the outcome are dependent on the cell type. MG selectively 
induces apoptosis in Jurkat cells (195,201). The mechanism of MG-induced apoptosis is 
cell type-dependent since several other cell lines were shown to be insensitive to MG. 
MG-induced cell death was mediated through JNK (c-Jun N-terminal kinase), showed 
typical apoptotic morphology (e.g. DNA fragmentation) and was dependent on caspase-
3. Administration of MG to rat mesangial cells induces apoptosis. This apoptosis is 
dependent on the activation of apoptosis signal-regulating kinase 1 (ASK1) through the 
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formation of ROS and is mediated by the p38α MAPK pathway (202). Up-regulation of p38 
MAPK pathway is also involved in the down regulation of glucose transporter-4 (GLUT4) in 
adipocytes (227). In human umbilical vein endothelial cells (HUVECs) MG triggers several 
pathways (200,228). A first pathway involves protein-tyrosine kinase (PTK) activation for 
tyrosine phosphorylation of several cellular proteins, leading to the activation of ERK. 
Another pathway triggered by MG is the induction of apoptosis. This signal transduction 
cascade is independent of PTK activity, but involves ROS induced activation of JNK, p38 
kinase and c-Jun. Interestingly enough, glyoxal, which differs from MG only by a methyl 
group, is only capable of inducing the first signal, but unable to induce the second. This 
strongly accentuates the specificity of MG as a signaling molecule.
 In retinal Müller cells and in microvascular endothelial cells from mouse kidney 
increased glycolysis leads to increased MG modification of the corepressor mSin3A. MG 
modification of mSin3A results in the recruitment of O-linked N-acetylglucosamine (O-
GlcNAc) transferase to an mSin3A-SP3 complex, leading to the O-GlcNAc modification 
of Sp3. This modification results in a decreased DNA-binding capacity of the repressor 
complex, thus changing the gene expression pattern of the respective cells (229,230). The 
extent of this modification is a direct reflection of intracellular MG concentrations which is 
determined by a variety of cellular processes. This suggests a possible function for MG as 
an integrator to co-ordinately regulate distinct patterns of gene expression. In the mouse 
fibrosarcoma cell line L929 tumor necrosis factor (TNF)-induced necrosis is dependent on 
the accumulation of MG. The formation of specific MG-derived modified protein is observed 
and these steps are important in these signaling processes (61).  
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Chapter 3: RAGE, the receptor for advanced glycation 
endproducts
3.1 Introduction
 One mechanism by which methylglyoxal-derived advanced glycation endproducts 
(MG-AGEs) exert their cellular function is through interaction with specific receptors. Various 
receptors and proteins that can bind to AGEs have been described, e.g. macrophage 
scavenger receptors type I and II (231-234), oligosaccharyl transferase-48 (AGE receptor 
1; AGE-R1) (235,236), 80K-H phosphoprotein (AGE-R2) (235,236), galectin-3 (AGE-
R3) (237), and lactoferrin and lysozyme (238). The one that has been studied the best, 
however, is the receptor for advanced glycation endproducts (RAGE) (239,240).
3.2 The receptor for AGEs
 RAGE was first isolated from bovine lung extract by affinity purification using 
AGE-modified albumin (240). RAGE is a member of the immunoglobulin superfamily 
of cell surface receptors. It is composed of one V-type and two C-type immunoglobulin 
domains which are extracellular, a single-pass transmembrane spanning domain and a 
short highly charged intracellular domain (239,241). The principal ligand binding domain 
is the V domain (242), however, one ligand, namely S100A6 has been reported to interact 
specifically with the C2 domain (243), hereby emphasizing the complex nature of RAGE 
signaling. Furthermore, recent reports indicate that the V domain and the C1 domain do not 
function as independent domains, but as a single structural unit (244). The highly charged 
cytoplasmic tail is important for signal transduction (241).
 At least three different major isoforms of RAGE exist, the full length RAGE 
(FLRAGE), an isoform described as a dominant negative RAGE (DNRAGE), lacking the 
intracellular domain, and a soluble RAGE (SRAGE), lacking both the intracellular domain 
and the transmembrane domain (Figure 3.1). These isoforms are the result of alternative 
splicing from a single RAGE gene (245), although some isoforms may be generated by 
protein cleavage (246). Other splice variants and polymorphism have also been described 
(reviewed in (247)).
 RAGE expression has been detected in all tissues and at a cellular level RAGE 
is found at the surface of most cell lines that have been examined (248). The correlation 
between mRNA levels, detected by Northern Blot, and protein levels seems small, indicating 
multiple levels of transcriptional, posttranscriptional and translational regulation. Of note is 
that RAGE expression is very low under physiological conditions, but under pathological 
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Figure 3.1. Major isoforms of RAGE.
Multiple isoforms of RAGE have been described. The three 
major isoforms are depicted and all contain an N-terminal 
V-type immunoglobulin domain and two C-type domains. 
SRAGE is not attached to the cell and has been hypothesized 
to attenuate RAGE signaling by capturing ligands prior to 
membrane interaction. DNRAGE does not posses a signaling 
function since it lacks the intracellular domain and therefore 
acts as a decoy receptor. SRAGE and DNRAGE could 
however exert a signaling function when involved in receptor 
complex formation. RAGE signaling is in part determined 
by the orchestrated effects of the different RAGE receptors. 
Adapted from (247).
conditions RAGE expression is strongly upregulated (249-252). 
3.3 Signaling through RAGE
 A striking feature of RAGE signaling is its multi-ligand character. These ligands 
include AGEs (242,253,254), amyloid-β peptide (Aβ) and β-sheet fibrils (255,256), several 
members of the S100/calgranulin family (257), amphoterin (often referred to as high 
mobility group box I (HMGB1) DNA-binding protein) (258,259), and Mac-1, a member 
of the β2-integrins (260). Multiple cellular signaling cascades have been shown to be 
activated by the binding of ligands to RAGE (Figure 3.2). The first signaling pathway to 
be described was the activation of p21ras through the induction of reactive oxygen species 
(ROS), leading to a cascade of mitogen-activated protein kinases (MAPKs) (261,262). This 
pathway has been reported in several cell types (263-266). The cytoplasmic tail of RAGE 
could function as a docking site for the extracellular signal-related kinase 1/2 (ERK1/2) 
MAPK (267). Other signaling pathways induced by the ligand binding of RAGE are other 
MAPK pathways, such as the p38 pathway and the stress-activated protein kinase/c-Jun 
N-terminal kinase (SAP/JNK) pathway (266,268-270), several JAK/STAT (Janus kinase/
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signal transducer and activator of transcription) pathways (271-273), the cdc42 and rac 
pathway of rho-GTPases (241), and the phosphoinositol-3-kinase (PI3K) pathway (274). 
Most of these pathways lead to activation of  NF-κB (nuclear factor-κB) (e.g. (241,261,263-
266,270,275,276)). Of note is that RAGE signaling hereby provides a positive feedback 
loop since the RAGE gene contains two NF-κB responsive elements in its promoter 
(277,278).
 The outcome of RAGE signaling is dependent on the cell type, the available ligands 
and their relative concentrations, the presence of additional splice variants and isoforms, 
the presence of RAGE polymorphisms and their different affinities for the available 
substrates, and the interplay between all of these different factors. An additional factor 
making RAGE signaling even more complex is the observation that some RAGE-mediated 
effects are independent of the cytoplasmic tail and only require the extracellular domain 
(284). This suggests engagement of RAGE in receptor complexes.
Figure 3.2. Schematic overview of signaling through RAGE.
Numerous signaling pathways can be initiated upon RAGE activation. Of note is the central role of NF-κB. 
Other transcription factors such as c-Jun are also involved in RAGE-mediated signaling. RAGE activation 
can also result in apoptosis, independent of gene-induction by activated transcription factors. 
See text for more details (recently reviewed in (279-283)).
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3.4 Involvement of RAGE in proliferation and survival
 Engagement of RAGE by one of its ligands can give rise to the activation of 
numerous key cell signaling pathways (see also above). The outcome depends on several 
parameters (e.g. cell type, ligand, ligand concentration, …). Several of these signaling 
cascades are important in the regulation of proliferation and cell survival, two processes of 
which the molecular pathways are closely intertwined. 
  Although several reports implicate the engagement of RAGE in the induction of cell 
division, RAGE signaling is also involved in differentiation. Proliferation and differentiation 
are separate and mutually exclusive events that must occur sequentially and in that order. 
Sajital and co-workers provided evidence for a role of amphoterin/RAGE signaling in 
growth retardation and survival of neuroblastoma cells when differentiation was induced 
with retinoic acid. RAGE was shown to play a significant role in cell survival by inducing an 
increase of the anti-apoptotic protein Bcl-2 (285). In rat L6 myoblasts amphoterin/RAGE 
interaction also stimulates differentiation and inhibits proliferation through the activation of 
the p38 pathway (286,287). Amphoterin activates RAGE partly in an autocrine manner in 
order to exert its activity on myoblasts (288). 
 When compared to normal tissue, a strong reduction in RAGE mRNA and even 
more in RAGE protein has been observed in lung cancer cells (289,290). This suggests 
that RAGE exerts an inhibitory activity on lung cell proliferation and promotes differentiation. 
Indeed, when full-length RAGE is over-expressed, proliferation is impaired and cells are 
rendered less responsive to proliferative stimuli. Activity of the p44/p42 MAPK pathway is 
decreased upon RAGE overexpression and the cells start to differentiate. A more direct 
link between RAGE and cell cycle control was seen in mesangial cells. Binding of AGE to 
RAGE leads to the activation of STAT5, which induces the p21waf gene, a potent inhibitor of 
cyclin dependent kinases (CDKs), key regulators of cell cycle (271). 
 RAGE, however, has also been described to promote proliferation. Taguchi and 
colleagues noted amphoterin/RAGE interaction induces lung tumor proliferation through 
activation of p44/p42, p38 and SAP/JNK MAP kinase pathways (268). Furthermore, RAGE 
stimulation with S100B or AGEs could function as a mitogenic stimulus in neuronal cells. 
Ligand binding of RAGE leads to the activation of the p44/p42 MAPK pathway and results 
in the upregulation and activation of cyclin D1/cdk4 and the transition into the S-phase 
(291).
 Of special interest is the complex nature of the involvement of amphoterin/RAGE 
interaction in T cell activation driven by dendritic cells. In response to inflammatory stimuli, 
dendritic cells actively secrete amphoterin. This amphoterin is extensively acetylated 
and serves as an autocrine ligand for RAGE activation, leading to a well-characterized 
differentiation program, referred to as maturation, through activation of p38, ERK1/2 (p44/
p42) and NF-κB. However, the secreted amphoterin also drives proliferation, survival and 
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polarization of naïve T cells through interaction with RAGE (292,293). 
 RAGE signaling has been shown to be involved in cell survival. Also here, RAGE 
exerts a very dualistic function, as it has been implicated in both the survival of cells as in 
the induction of cell death, sometimes even in the same cell type. Activation of RAGE by 
amphoterin can promote cell survival by inducing expression of Bcl-2 (B cell lymphoma-
2) through activation of NF-κB (294). These effects, however, are seen when nanomolar 
concentrations of amphoterin are present. When, on the other hand, micromolar 
concentrations of amphoterin are present, apoptosis was induced. The latter outcome was 
dependent on the induction of ROS, which led to the activation of mitogen extracellular 
kinase (MEK) and consequent cytochrome c release from mitochondria and caspase-
3 activation. Furthermore, when S100P activated RAGE in an autocrine manner, ERK 
mediated NF-kB activation leads to proliferation and survival (295,296). This dual role for 
RAGE is also observed in neuronal cells, where low concentrations of S100B protect cells 
against hypoxia or ischemia-induced apoptosis, whereas high concentrations of S100B 
exert a RAGE-mediated cytotoxic effect (249). On the other hand, AGE-modified collagen 
induces caspase-3, -8, and, to a lesser extent, -9 dependent apoptosis upon binding to 
RAGE (297,298).
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Chapter 4:  Growth factors
4.1 Introduction
 
 Growth, proliferation and survival of cells are highly regulated processes and 
in multicellular organisms depend on the presence of extracellular stimuli (299). The 
availability of growth factors (GFs) seems decisive herein (300). These GFs control cell 
survival, either through the inhibition of the intrinsic apoptotic pathways or by actively 
promoting survival. Both mechanism are strongly intertwined and rely partly on the same 
signaling pathways. Also, it is clear that neither of the mechanisms is sufficient on its own, 
both are needed to maintain cell size and viability (301-307). Literature on this subject 
is vast. A large number of cytokines exist, the web of downstream signaling pathways is 
complex, and the outcome is largely dependent on the cell type, making knowledge on this 
matter fragmentary. Valuable tools in the study of GF signaling are hematopoietic cells. For 
their survival, these cell lines depend on well defined GFs, such as interleukin-3 (IL-3), -2 
or -7. A central mediator of interleukin signaling is the phosphoinositol-3-kinase (PI3K) and 
Akt/protein kinase B (PKB) pathway (308-313). A simplified schematic overview of PI3K/
Akt signaling is given in figure 4.1. Akt is a versatile kinase with numerous substrates and 
Akt signaling contributes to diverse physiological processes, including the regulation of 
apoptosis, the regulation of the cell cycle and the regulation of glucose metabolism.
Figure 4.1. The PI3K/Akt 
pathway has a central role 
in growth factor signaling.
Binding of GFs to their 
receptors leads to activation 
of PI3K, either directly or 
indirectly through scaffolding 
adaptors such as insulin 
receptor substrate-1 (IRS-
1). These events ultimately 
lead to the activation 
of Akt. Subsequently 
numerous substrates can 
be phosphorylated by Akt. 
This phosphorylation can 
lead to either activation 
(arrows) or inactivation 
(blocking arrows). Two 
major downstream branches 
in Akt signaling are the 
mTOR pathway, which gets 
activated by Akt, and the GSK-3 pathway, which gets inactivated by Akt phosphorylation. Several downstream 
targets are shown, which are regulated directly by Akt or indirectly through the mTOR or GSK-3 branch. These 
targets illustrate how Akt signaling is involved in the regulation of different physiological processes, such as 
apoptosis, the cell cycle and glucose metabolism (see text for further discussion of these processes). Of 
note, both GSK-3 and mTOR signaling lead to inhibition of IRS-1, hereby negatively regulating Akt signaling. 
Recent reviews about  PI3K/Akt signaling are (314,315), see text for more references.
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1 The control and regulation of mitochondria-related apoptotic events occurs through members of the Bcl-2 
(B cell lymphoma 2) family of proteins. Based on the presence of conserved Bcl-2 homology (BH) domains, 
and their functions, three subfamilies can be described (310,311).
 The anti-apoptotic Bcl-2 proteins, such as Bcl-2, Bcl-xL and Mcl-1, contain all four BH-domains. 
The pro-apoptotic proteins can be separated into two sub-families. First there is the multidomain Bcl-2 
family, including Bax and Bak. This family shares three BH-domains, but lacks the N-terminal BH4 domain 
(312,313). And finally there is the pro-apoptotic BH3-only subfamily, containing only the BH3 domain. This 
family includes e.g. Bid, Bad, Bim, Puma, Noxa (314-318).
4.2 Growth factors inhibit intrinsic apoptosis
 In the absence of appropriate GFs cells, by default, undergo apoptosis (316) 
(Figure 4.2). Members of the BH3-only subfamily of the Bcl-2 family1 are activated upon 
GF-withdrawal. Once activated, these BH3-only members promote apoptosis, most likely 
by antagonizing the prosurvival anti-apoptotic Bcl-2 family members such as Bcl-2, Bcl-
xL and Mcl-1 or by facilitating the activity of the pro-apoptotic Bcl-2 family members Bax 
and Bak (321,323-328). Bax and Bak subsequently participate in the permeabilization of 
the outer mitochondrial membrane, hereby releasing prodeath factors like cytochrome c, 
Smac, apoptosis-inducing factor (AIF), and endonuclease G. Release of cytochrome c 
then leads to the activation of caspase-9, which in turn activates caspase-3 (329-331). 
Numerous studies indicate that Bad is the BH3-only member involved in GF withdrawal-
induced apoptosis (332-335). Recent reports, on the other hand, claim that, not Bad, but 
Puma or Bim are involved (336-339).
 GF signaling can intersect with this default apoptosis at several levels. A critical step 
in the induction of apoptosis is the permeabilization of the outer mitochondrial membrane 
and the subsequent release of cytochrome c. An important manner in which GFs inhibit 
apoptosis is, therefore, upstream of this event, by directly hampering the action of the 
BH3-only proteins. Proteins like Bad, Bim and Puma are under tight transcriptional control 
and are regulated at the posttranslational level. The best studied example herein is Bad. 
GFs are able to induce multiple phosphorylations of Bad (309,342-346), hereby marking 
it for binding to 14-3-3 proteins (342,347-351) or blocking its interaction with Bcl-2 and 
Bcl-xL (352-354) and inactivating its pro-apoptotic function. The same mechanism has 
been shown to be involved in the regulation of the activity of Bim (338). GFs also regulate 
the BH3-only proteins at the transcriptional level in part by inactivating the forkhead 
transcription factors (336-339,355-357). In addition, GFs counter apoptosis by inducing the 
expression of anti-apoptotic members of the Bcl-2 family, partly through the activation of 
NF-κB (358-366). It is interesting to note that GFs can also regulate this intrinsic apoptotic 
pathway downstream of cytochrome c release. This inhibition can be obtained in part by 
the direct phosphorylation of caspase-9 (367-369). 
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Figure 4.2. Growth Factor withdrawal leads to mitochondria-dependent 
apoptosis.
Upon the withdrawal of GFs Bax and Bak are activated by the BH3-only proteins (e.g. Bad, 
Bim, …), leading to the permeabilization of the outer mitochondrial membrane and the 
subsequent release of cytochrome c and other prodeath factors from the intermembrane 
space. The precise mechanism of Bax/Bak activation is still unclear. Either BH-3 only 
proteins bind to and neutralize anti-apoptotic Bcl-2 proteins, leading to the release of 
Bax and Bak, or BH3-only proteins can interact directly with Bax and Bak. The released 
cytochrome c, together with Apaf-1 and caspase-9, forms the apoptosome. Smac/
Diablo and Omi/HtrA2 relieve the inhibition of caspases induced by IAP. Subsequently 
the executioner caspase-3 is activated, which results in apoptosis. AIF, endonuclease 
G, Omi/HtrA2 and the dysfunctioning of the mitochondria further contribute to cell death 
in a caspase-independent manner (for reviews see (328,340,341)). 
4.3 Growth factors regulate metabolism 
 Although the most obvious way for GFs to regulate survival is by inhibiting apoptosis 
(see above), GFs are dependent on the presence of nutrients to exert their function 
(306,370,371). A key indication for this is the observation that even the presence of Bcl-
2 or the deficiency of pro-apoptotic Bcl-2 family members fails to rescue cells from cell 
death upon GF withdrawal (301,372-376). Instead, in the absence of GFs, cells undergo 
progressive atrophy, ultimately leading to cell death (304,371,377). It is becoming clear 
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that metabolism is not merely driven by increasing metabolic demands, due to GF-driven 
proliferation. GFs directly regulate metabolism, in parallel to growth, proliferation and 
survival (378,379). A decrease or inhibition of glucose metabolism can lead to the initiation 
of cell death and, inversely, GF withdrawal-induced cell death is associated with a reduced 
glucose metabolism (380). 
 A first key step in the regulation of glucose metabolism is the uptake of glucose 
through facilitative glucose transporters, such as Glut1, the predominant glucose 
transporter in hematopoietic cells (Figure 4.3). A strong correlation is seen between the 
ability of GFs to maintain viability and the expression of glucose transporters (380,381). It 
has also been shown that overexpression of Glut1 can delay the onset of GF starvation-
induced apoptosis in IL-3 dependent cells, although this Glut1 overexpression does not 
maintain long-term survival (306). An important mechanism by which GFs regulate glucose 
uptake is by promoting localization and retention of Glut1 on the cell surface (379,382). 
GF withdrawal leads to a rapid decline in membrane expression of Glut1, which can be 
prevented by activation of PKB/Akt signalling (303,305,306,371,372,383). In addition to the 
regulation of glucose uptake, GFs have been shown to regulate the membrane expression 
of several other nutrient transporters, like 4F2hc, an amino acid transporter, transferrin 
receptor, and low-density lipoprotein (LDL) receptor in a PKB/Akt and mTOR-dependent 
fashion (384-386).
Figure 4.3. Schematic overview of the regulation of the metabolism by Growth Factors.
GLycolytic metabolism is regulated at several steps by GFs. Also the membrane localisation of numerous 
nutrient transporters is under the control of GFs. See text for more details (adapted from (378,387)).
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 Besides determining the uptake of glucose and metabolites, GFs strongly regulate 
glycolysis itself (Figure 4.3). Upon GF withdrawal, the flux of glucose through the glycolitic 
pathway declines and the production of L-lactate drops (303,306,388). Rate-determining 
steps in glycolysis are the steps catalyzed by hexokinase (HK) and  phosphofructokinase 1 
(PFK-1) and a decrease in reaction rate of either one of these enzymes results in a decrease 
in the overall rate of glycolysis. HK mediates the first committed step of glycolysis, the 
phosphorylation of glucose to glucose-6-phosphate. GF stimulation leads to an increase 
of HK expression levels and HK activity (306,389-392). Several reports have confirmed 
a general association between high levels of HK activity and cell survival (370,393,394). 
Furthermore, it has been described that overexpression of HK is able to attenuate 
apoptosis (305,370,395,396). The most important rate-limiting committed step in glycolysis 
is the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate, catalyzed by PFK-
1. Besides regulating the expression level (306,397), GFs also control the activity of PFK-2 
(phosphofructokinase 2) (397-401). PFK-2 is activated by phosphorylation and this leads 
to an increase of fructose-2,6-bisphosphate, an important allosteric activator of PFK-1 
(402). In addition, other enzymes involved in metabolism, such as lactate dehydrogenase 
(LDH) and triosephosphate isomerase, are regulated by GFs (389).
4.4 Growth factors maintain mitochondrial physiology
 For a long time the maintenance of metabolism and the inhibition of apoptosis were 
considered to be independent pathways and were studied as such (306,309,331,352,3
53,370). A central point in the induction of apoptosis is the permeabilization of the outer 
membrane of the mitochondria, which leads to the release of cytochrome c and other pro-
apoptotic proteins. A decrease in metabolism would lead to a perturbation of mitochondrial 
physiology, resulting in a subsequent rupture of the outer membrane (304,403,404). 
On the other hand, Bcl-xL is capable of preventing apoptosis, even in the absence of 
glucose or GF stimulation (370,388), suggesting that the regulation of metabolism and 
induction of apoptosis can be dissociated. Several reports, however, point towards a role 
for HK in the regulation of mitochondria-dependent apoptosis. HKs are known to reside 
in mitochondria upon GF stimulation and to bind to the voltage-dependent anion channel 
(VDAC) (370,405). The VDAC is a β-barrel protein, spanning the outer mitochondrial 
membrane and has been implicated in the induction of apoptosis (406,407). Mitochondrial 
bound HK is able to attenuate the induction of apoptosis by antagonizing the activity of 
Bax and Bak (396,408,409). In liver mitochondria HK IV and Bad have been shown to 
reside in a holoenzyme complex (307). The phosphorylation status of Bad influences HK 
activity and HK activity is required in order to keep Bad phosphorylated. This mechanism 
provides strong evidence for the coordination of apoptosis and glycolysis and indicates 
an interdependence between pathways preventing apoptosis and pathways promoting 
survival.
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4.5 Regulation of the cell cycle is under control of growth factors
 Besides preventing apoptosis and stimulating metabolism (see above), GFs are 
known to exert another function, namely the induction of proliferation. Overexpression of 
Bcl-2 or Bcl-xL can protect cells from GF withdrawal-induced apoptosis, but cells undergo 
growth arrest (404,410,411). Mammalian cells depend on GFs for the regulation of the 
transgression through the cell cycle (Figure 4.4). It has been known for a long time, 
however, that this dependency does not last throughout the entire cell cycle. Already during 
G1 phase, several hours before the entry into S phase, the restriction point (R) is defined 
as the moment when a transition occurs from GF dependence to GF independence. 
After R, cells can complete their division cycle irrespective of the presence of mitogenic 
signals (412-414). Cell cycle progression relies on a highly regulated chain of signaling 
and transcriptional events, involving the sequential transcription and activation of cyclin 
dependent kinases (CDKs, reviewed in (415)). Important herein is the phosphorylation 
state of the retinoblastoma protein (pRb) (416). pRb binds to the E2F family of transcription 
factors (417,418) and to chromatin remodeling enzymes, such as histone deacetylase 1 
and 2 (419,420), hereby inhibiting their activity and suppressing cell cycle progression. 
In early G1 pRb is hypophosphorylated and exerts its inhibitory activity. In order to pass 
from G1 to S phase the cyclin D-CDK4/6 complex partially phosphorylates pRb, causing 
the release of the E2F family of proteins. Many promoters of genes which are important 
for cell cycle progression, such as cyclins E (421) and A (422) are activated by E2F 
proteins. Subsequently pRb is further phosphorylated by the cyclin E-CDK2 complex, 
hereby intensifying the transcription of E2F-regulated genes, leading to G1-S transition. 
Phosphorylation of pRb and the subsequent induction of cyclin E are often considered to 
be the molecular mechanism behind R, although this is contested by several reports (423-
426).
 GFs regulate cell cycle entry and G1-S transition mainly by lowering the concentration 
of CDK inhibitors, consisting of the inhibitors of CDK4 (INK4) and the more broadly 
acting Cip/Kip families, and by regulating the levels and activity of cyclins and CDKs 
(415,427,428).
 The withdrawal of GFs results in two distinguishable and sequential responses. 
The first response is a cell cycle arrest, which is followed by apoptosis. Moreover, not only 
do these processes differ kinetically and mechanistically, it has been shown that lower 
concentrations of GFs suffice to protect cells from apoptosis, but are not able to induce 
cell division (429). Of note is the observation that Bcl-2 family proteins have regulatory 
properties in cell cycle. Bcl-2 and Bcl-xL are known to enhance G0 arrest and significantly 
delay cell cycle progression, in part, by inducing p27Kip1 expression (430-434). These 
effects on cell cycle can not be separated from the prosurvival functions and can be 
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countered by Bad and Bax (435-437). Recent reports that pro-apoptotic proteins like Bad 
and caspase-9 are regulated in a cell cycle-dependent manner underline how much cell 
cycle and apoptotic signaling are interlaced (367,368,438). By combining the regulation of 
these processes, GFs might provide protection against inappropriate proliferation.
Figure 4.4. Schematic overview of the cell cycle.
Several phases can be distinguished in the cell cycle; G1 (gap 1), S (DNA synthesis), G2 (gap 2) and 
M (mitosis). Late in G1, cells become independent of GFs to complete their division cycle. This point is 
referred to as the restriction point (R). Formation and activation of cyclin-cdk complexes determines the 
progression of the cell cycle and is strictly regulated throughout the different phases. The presence and 
activity of the respective complexes is indicated with arrows. A central role of the cyclin-cdk complexes is the 
phosphorylation of retinoblastoma protein (pRB), a general cell cycle inhibitor that prevents G1-S transition by 
repressing E2F dependent transcription. The role of GFs is the regulation the levels and activity of G1 cyclins 
and CDKs and lowering the levels of inhibitory proteins. Withdrawal of GFs renders cells incapable of passing 
R and results in G1 arrest. See also text for more details.
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Scope of the thesis
 The requirement of growth factors (GFs) is of fundamental importance in 
physiological homeostasis. For unicellular organism growth regulation is mainly controlled 
by the availability of nutrients. However, for multicellular organism an additional regulatory 
mechanism is indispensable. Here nutrient availability is normally not limiting and thus 
does not suffice to control cellular growth and division in multicellular organisms. This 
additional regulatory mechanism is provided by the dependence on GFs. GFs exert their 
activity by regulating several fundamental processes, such as metabolism, proliferation 
and survival. Although these processes are regulated as independent branches of GF-
induced signaling, extensive crosstalk is needed between them. 
In this context we set out to study the involvement of the ubiquitous and highly 
conserved glyoxalase system and its physiological substrate methylglyoxal, an unavoidable 
by-product of glucose metabolism, in the regulation of cell death and cell cycle. Earlier 
findings in our group demonstrated that phosphorylated glyoxalase I and its substrate 
methylglyoxal are important in TNF-induced cell death in the fibrosarcoma cell line L929. 
However, the ubiquitous nature of the glyoxalase system and the inevitable presence of 
methylglyoxal under physiological conditions, suggest a more fundamental role. The scope 
of this study was to investigate the potential involvement of phosphorylated glyoxalase 
I in the GF-withdrawal induced G1 arrest and apoptosis and in the regulation of the 
cell cycle.
Research in mammalian cells, as well as in prokaryotic and plant cells indicate a 
strong correlation between the rate of growth on the one hand and the expression level 
and/or activity of glyoxalase I on the other. However, a mechanistic link has never been 
found. We therefore investigated whether the phosphorylation of glyoxalase I might be 
involved in the regulation of the cell cycle. Two cellular model systems were used to study 
the posttranslational modifications and activity of glyoxalase I in detail. First Ba/F3 cells 
were depleted of IL-3 to induce G1 arrest and subsequently apoptosis. GF starvation has 
been shown to result in a significant decline in glucose metabolism. This would result in 
a change in intracellular levels of methylglyoxal, making this an attractive model system 
to study the glyoxalase system and possible modulation of the detoxification of MG. 
Concurrently attention was given to the formation of specific methylglyoxal-derived 
advanced glycation endproducts (MG-AGEs) and we attempted to situate these events 
in progression of the IL-3 depletion induced signaling. Time course experiments were 
also performed on IL-3 dependent Ba/F3 cells going through the cell cycle synchronously. 
Finally, in vitro studies were commenced to further explore the pathway upstream of the 
phosphorylation of glyoxalase I.
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 A possible mechanism used by MG-AGEs to exert their influence on the cell cycle 
and/or apoptosis is through activation of the Receptor for Advanced Glycation Endproducts 
(RAGE). This multiligand receptor has been reported to be involved in numerous cellular 
processes, including proliferation and survival. A dual role has been imputed on RAGE 
in both processes. RAGE has been involved in proliferation as well as in differentiation, 
and in survival as well as in cell death. The aim of the second part of this thesis was thus 
dedicated to the study of RAGE during GF-depletion induced G1 arrest apoptosis, and 
during the cell cycle.
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depletion via a GSK-3β-dependent  mechanism
INTRODUCTION
 The main function of the glyoxalase system, comprising glyoxalase 1 and 2 (GLO1 
and 2), is to detoxify reactive and cytotoxic -oxoaldehydes, mainly methylglyoxal (MG) 
(1-3). After its discovery in 1913, a function of the glyoxalase system in glycolysis was 
hypothized. However, this could not be proven (4) and, until today, the full biological 
function of the glyoxalase system has not been elucidated, but its ubiquitous nature 
suggests a fundamental and conserved role in life (4,5). In the 1960s and 70s the work 
of Szent-Gyorgyi indicated a regulatory role for GLO1 and its substrate MG in the control 
of cell division (for an overview see (1)), but a mechanistic link was never established. 
However, more and more recent evidence indicates that GLO1 may indeed play a role in 
the control of cellular growth. For instance, in plants it has been shown that there is a strong 
correlation between cell proliferation and the expression levels of GLO1, being the highest 
in strongly proliferating tissues (6). Also in yeast a strong correlation between growth status 
and GLO1 activity has been described (7). Along with an induction of cell proliferation, the 
plant growth hormone auxin induces the expression and activity of GLO1 (8). Gibberellin, a 
growth regulator in plants, induces phosphorylation of GLO1 (9), and calmodulin, a protein 
involved in cell growth, stimulates GLO1 activity (10). 
 Methylglyoxal is a cytotoxic by-product of normal metabolism. The main source is 
the enzymatic and nonenzymatic dephosphorylation from glyceraldehyde-3-phosphate 
and dihydroxyacetone phosphate, both intermediates of glycolysis (for reviews on MG see 
(1,3)). MG is very reactive and under physiological conditions MG reacts nonenzymaticaly 
with arginine residues mainly (11), but also with lysine and cysteine residues (12). Under 
normal conditions MG is detoxified by the GLO system to D-lactate using reduced 
glutathione (GSH) as a cofactor (13). Pathophysiological conditions can cause a rise of 
MG concentrations and Advanced Glycation Endproducts (AGEs) can be formed (for an 
overview see (14)). These AGEs are involved in the development of pathophysiological 
processes in vivo. Reports show that MG is able to inhibit growth. This growth inhibition 
shows a cell type selectivity and is dependent on divers mechanisms (15-22).  
We have previously discovered a phosphorylated form of GLO1 and, in a tumor cell death 
model, we showed that the TNF-induced phosphorylation of GLO1 is required for cell 
death. Furthermore, phosphorylated GLO1 is not involved in the detoxification of MG, but 
instead mediates the cytotoxic effects of MG via a pathway that leads to MG-modification 
of specific target molecules (MG-derived AGE formation). However, the real biological 
function of phosphorylated GLO1 remains to be determined. (23,24).
 Mammalian cells require stimuli from other cells in order to counter the intrinsic 
apoptosis machinery (25,26). This serves as a mechanism to ensure cells only survive 
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in the proper context. Cell death is inhibited partly by interfering directly with apoptosis. 
Anti-apoptotic proteins are up-regulated or activated (27-30) and pro-apoptotic proteins 
are down-regulated or inactivated (31-38). Another important mechanism by which growth 
factors may prevent apoptosis is by regulating basic cellular physiology by promoting 
nutrient uptake and cellular metabolism (30,39-42). A key regulator in apoptotic signaling 
is glycogen synthase kinase 3β (GSK-3β (see reviews (43,44)). Also in growth factor 
deprivation-induced apoptosis, GSK-3β has an important regulatory role (45-48).
 In this report we show that depletion of IL-3 induces a phosphorylation of GLO1. 
This phosphorylation is partly mediated by GSK-3β as inhibition of GSK-3β also inhibits 
part of the phosphorylation of GLO1. This phosphorylation doesn’t show an effect on the 
detoxification of MG by GLO1 and it occurs before the onset of apoptosis. Also we show 
that specific MG derived AGEs are formed, which also can be prevented by inhibition of 
GSK-3β.
MATERIALS AND METHODS
Cell Lines and Cultures 
 The IL-3 dependent pro-B cell line Ba/F3 (49) was purchased from DSMZ. Ba/
F3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with glutamax 
(Invitrogen) supplemented with heat-inactivated FCS (10% v/v) (Cambrex), penicillin (100 
units/ml) and streptomycin (0.1 mg/ml) and 5% conditioned medium from WEHI-3B cells 
as a source of mouse IL-3. Ba/F3 cells were cultured at 37°C in a humidified incubator 
under an 5% CO2 atmosphere. HekT cells, NIH3T3 cells and L929 cells were cultured 
in DMEM with glutamax (Invitrogen) supplemented with heat-inactivated FCS (10% v/v), 
penicillin (100 units/ml) and streptomycin (0.1 mg/ml) at 37°C in a humidified incubator 
under an 8% CO2 atmosphere. The acute myeloid leukemia cell line HL-60 was a kind 
gift from J. Van Der Heyden. The cells were maintained in RPMI 1640 with L-glutamine 
(Invitrogen) supplemented with 10% heat-inactivated FBS and penicillin (100 units/ml) and 
streptomycin (0.1 mg/ml) and were cultured at 37°C in a humidified incubator under an 5% 
CO2 atmosphere. 
Cell stimulations
IL-3 was removed by washing exponentially growing cells 3 times in culture medium 
without conditioned WEHI-3B medium and resuspended in culture medium without 
conditioned WEHI-3B medium in the absence or presence of indicated concentrations 
of methylglyoxal (Sigma), N-acetyl-L-cycteine (NAC; Sigma), LiCl (Fluka), SB216763 
(Sigma), SB203580 (Sigma) or Z-VAD-FMK (Promega).
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HL-60 cells were depleted of FBS by washing exponentially growing cells 3 
times in culture medium without FBS and resuspended in FBS-free culture medium at a 
concentration of 1 X 106 cells/ml. NIH3T3 cells were depleted by washing them 3 times 
with culture medium without FBS and subsequently cultured in culture medium containing 
0.5% (v/v) FBS.
 
DNA distribution analysis
 Cells were stained with propidium iodide (PI, Sigma) containing staining solution 
(50) and analyzed by a FACSCalibur flow cytometer (488Ex/590Em). Cell Quest software 
was used to analyze cell cycle distribution (FACS Calibur, Becton Dickinson) (50,51). Ten 
thousand cells were routinely analyzed.
Electrophoresis and immunoblotting
The cells were washed 3 times with ice-cold PBS buffer and lysed with cytosol 
extraction buffer (10 mM Tris-HCL pH7.4, 50 mM EDTA pH8.0, 25 mM NaCl, 0,7% 
TritonX-100, 100 mM PMSF, 1 tablet Complete Protease Inhibitor Cocktail (Roche)/50 ml 
cytosol extraction buffer). Cell lysates were cleared by centrifugation (14,000 x g). Protein 
concentrations were determined using Bradford method. Proteins were separated by 
SDS-PAGE and transferred onto a PVDF membrane (Hybond-P, Amersham Pharmacia 
Biotech). The blots were incubated with the desired antibodies followed by ECL-based 
detection (Amersham Pharmacia Biotech).
2-Dimensional Gel Electrophoresis 
Isoelectric focusing was carried out on 18 cm IPG strips, pH 4-7 (GE Healthcare) 
according to the manufacturer’s instructions. For the second dimension, proteins were 
separated by SDS-polyacrylamide gel electrophoresis (PAGE, 12%).
Assay of glyoxalase1 activity
 GLO1 activity was determined by using a spectrophotometric method, which 
monitors the initial rate of change in absorbance at 240 nm caused by the formation of S-D-
lactoylglutathione (52). The standard assay mixture contained 2-mM MG and 2-mM GSH 
in a sodium phosphate buffer (50 mM, pH 6.6, 20°C). The reaction mixture was allowed to 
stand for 10 min at 37°C before the addition of the cytosolic protein fraction to ensure the 
equilibration of hemithioacetal formation.
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Figure 6.1. Time course of GLO1 phosphorylation in IL-3 depleted Ba/F3 
cells.
Ba/F3 cells were depleted of IL-3 and lysed after indicated periods of time. 
Cells were lysed in CEB and after ethanol precipitation resuspended in 2-DE 
lysis buffer. Protein concentrations were determined and 200 µg of the lysates 
was loaded for separation by 2-dimensional gel electrophoresis (pH 4-7). 
Representative western blots of 2-DE gels developed with a polyclonal anti-
human GLO1 antibody (6) are shown. A reference spot α, which corresponds 
to the non-NO-responsive form of GLO1 is indicated (6).
Measurement of D-Lactate
 A fluorimetric method was used as previously described (53). Briefly, D-Lactate 
formation is measured by the formation of NADH during oxidation of D-Lactate by a D-
lactate dehydrogenase.
RESULTS
Glyoxalase I is phosphorylated upon IL-3 starvation.
 We recently described that most cell types, analysed so far express multiple isoforms 
of glyoxalase1 (GLO1), including a NO-responsive form and a non-NO-responsive form, 
which we designated as the α-isoform (23). These isoforms can be separated by 2-
dimensional gel electrophoresis (2-D) and detected by Western blotting using an anti-
GLO1 antibody. We previously discovered phosphorylated GLO1 by means of cell labeling 
with 32P-orthophosphate (24). Multiple phosphorylation of GLO1 can occur either on the 
NO-responsive form or the α-isoform and this can be monitored in 2-D gels by a shift of the 
isoform to the acidic side of the gel (23). 
 To investigate whether phosphorylation of GLO1 was related to growth factor 
signaling in mammalian systems, Ba/F3 cells, which are dependent on IL-3 for survival 
and proliferation, were depleted of IL-3 and cell lysates were prepared at the indicated 
time points cells. The samples were analysed by high-resolution 2-D in combination with 
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Figure 6.2. Phosphorylation of GLO1 in different cell lines.
A. Phosphorylation of GLO1 in NIH3T3 cells. NIH3T3 cells were washed in culture medium without FBS and 
cultured in the presence of 0.5 % FBS. Cells were lysed in CEB after 1 hour and after ethanol precipitation 
resuspended in 2-DE lysis buffer. Protein concentrations were determined and 400 µg of the lysates was 
loaded for separation by 2-dimensional gel electrophoresis (pH 4-7). Cells were lysed in CEB and after 
ethanol precipitation resuspended in 2-DE lysis buffer. Representative western blots of 2-DE gels with 
a polyclonal anti-human GLO1 antibody are shown. B. Phosphorylation of GLO1 in HL-60 cells. HL-60 
cells were depleted of FBS and lysed after 1 day. Cells were lysed in CEB and after ethanol precipitation 
resuspended in 2-DE lysis buffer. Protein concentrations were determined and 200 µg of the lysates was 
loaded for separation by 2-dimensional gel electrophoresis (pH 4-7). Cells were lysed in CEB and after 
ethanol precipitation resuspended in 2-DE lysis buffer. Representative western blots of 2-DE gels with a 
polyclonal anti-human GLO1 antibody are shown. C. Serum starvation-induced apoptosis in HL-60 cells. 
HL-60 cells were depleted of FBS. Apoptosis was measured by the analysis of the percentage of cells with 
sub-diploid DNA at the indicated time points.
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Western blotting using a polyclonal antibody raised against GLO1 (Figure 6.1). As shown 
in the upper panel (0h), the isoform pattern of GLO1 in Ba/F3 cells is identical to the one 
we described previously for several other mouse and human cell types (23). The most 
basic isoforms corresponds to the NO-responsive form of GLO1 and the non NO-modified 
form of GLO1 is indicated by α. After one hour of IL-3 starvation, the most basic isoform 
has shifted to the acidic side, which is indicative for phosphorylation (spot indicated by an 
arrow). After three hours of IL-3 starvation, the relative amount of the NO-responsive form 
of GLO1 is reduced and had become partially dephosphorylated (shifted more to the basic 
side as compared to the 1h time point). After five hours IL-3 starvation, the NO-responsive 
form of GLO1 is completely disappeared and phosphorylation of GLO1 is induced on the 
non-No-responsive form (phosphorylated spots are indicated by an arrow). Note that the 
total amount of phoshorylated GLO1 at 5h of IL-3 starvation is relatively high as compared 
to the previous time points of IL-3 starvation. In several independent experiments, we also 
noticed that the time course and degree of phosphorylation of GLO1 induced by depletion 
of IL-3 could vary according to the experiment and could be induced either earlier or later 
as shown in Figure 6.1.  
Growth Factor withdrawal induced phosphorylation of GLO1 is not exclusive for IL-
3
To examine whether phosphorylation of GLO1 was specific for IL-3 depletion or 
whether it was a more general phenomenon, the phosphorylation of GLO1 upon GF 
depletion was also examined in two other cell lines.
 Mouse fibroblasts are commonly used in the study of serum dependence. After 
serum withdrawal mouse fibroblasts reversibly exit the cell cycle (54-57) and after a 
sustained absence of GFs they undergo apoptosis (58,59). The mouse fibroblast cell line 
NIH3T3 was serum-starved as described in M&M. As shown in Figure 6.2A immunoblots 
of lysates of cells that were maintained in culture medium with 0.5 % FBS display GLO1 
is phosphorylated on the non NO-modified form of GLO1. Immunoblots of lysates from 
cells that were kept in culture medium with 10 % FBS show that this spot was absent. This 
phosphorylation occurs after 1 hour of starvation, well before the onset of apoptosis.
 Another cell line tested was the human leukemia cell line HL-60. HL-60 is a 
hematopoietic cell line, like Ba/F3 cells, albeit of the myeloid lineage, whereas Ba/F3 cells 
are lymphoid cells. It has been reported that HL-60 cells are sensitive to exogenous MG, 
making HL-60 very interesting to study possible effects on the GLO system. Addition of MG 
will cause G1 growth arrest and induce apoptosis in HL-60 cells (19). Upon serum depletion 
HL-60 also arrest growth and induce apoptosis (60,61). Analysis of immunoblots detected 
with an anti-GLO1 antibody shows the induction of phosphorylation of GLO1 upon serum 
starvation (Figure 6.2.B). When compared to the control situation the spot second to the 
right disappeared and a more acidic new spot appears. Although lysates were made after 
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Figure 6.3. Inhibition of GSK-3 interferes with phosphorylation of GLO1.
A. Effect of GSK-3 inhibition on IL-3 depletion-induced apoptosis. Ba/F3 cells were depleted of IL-3 in the 
presence or absence of the indicated inhibitor. Apoptosis was measured by the analysis of the percentage of 
cells with sub-diploid DNA at the indicated time points. B and C. GLO1 phosphorylation in IL-3 depleted Ba/
F3 cells in the presence of GSK-3 inhibitors. Ba/F3 cells were depleted of IL-3 and cultured in the presence 
or absence of LiCl (A) or SB216763 (B). Cells were lysed in CEB after 3 hours and after ethanol precipitation 
resuspended in 2-DE lysis buffer. Protein concentrations were determined and 200 µg of the lysates was 
loaded for separation by 2-dimensional gel electrophoresis (pH 4-7). Representative western blots of 2-DE 
gels with a polyclonal anti-human GLO1 antibody are shown. Concentrations used are LiCl: 20 mM and 
SB216763: 20 µM.
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Figure 6.4. Phosphorylation of GLO1 does not 
affect the formation of D-lactate.
A. A time course of D-lactate formation in Ba/F3 
cells. Ba/F3 cells were washed in culture medium 
without IL-3 and subsequently cultured in the 
presence or absence of IL-3. At indicated time 
points the presence of D-lactate in the medium was 
measured by detection of the formation of NADH 
upon incubation with D-lactate dehydrogenase. B 
and C. D-lactate production in IL-3 depleted Ba/F3 
cells in the presence of GSK-3 inhibitors. Ba/F3 cells 
were depleted of IL-3 and cultured in the presence or 
absence of LiCl (B) or SB216763 (C). The presence 
of D-lactate in the medium was measured after 
indicated time intervals. Concentrations used are 
LiCl: 20 mM and SB216763: 20 µM.
Figure 6.5. In vitro GLO1 activity is not altered 
by phosphorylation.
A. A time course of GLO1 activity in IL-3 starved 
Ba/F3 cells. Ba/F3 cells were washed in culture 
medium without IL-3 and subsequently cultured 
in the presence or absence of IL-3. At indicated 
time points cells were lysed in CEB. Lysates were 
brought to equal concentrations and cell lysates 
were used to assay GLO1 activity. B. GLO1 activity 
in IL-3 depleted Ba/F3 cells in the presence of 
GSK-3 inhibitors. Ba/F3 cells were washed in 
culture medium without IL-3 and subsequently 
cultured in the presence or absence of IL-3 and 
LiCl was added. At indicated time points cells 
were lysed in CEB. Lysates were brought to equal 
concentrations and cell lysates were used to assay 
GLO1 activity. Reaction rates were determined 
using Ultraspec 1100  software (Amersham, BD 
Biosciences) and are shown relative to the reaction 
rate of lysates made of exponentially growing 
cells, which are set as 100%. LiCl was added in a 
concentration of 20 mM.
24 hours of serum starvation, phosphorylation is still induced before the onset of apoptosis, 
which is only observed after 72 hours of serum starvation (Figure 6.2.C). 
 In conclusion, the data presented here show that the phosphorylation of GLO1 upon 
GF withdrawal is not restricted to Ba/F3 cells, but can also occur in mouse fibroblasts and 
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human leukemic cells upon GF withdrawal. It may therefore represent a more general 
mechanism. This hypothesis is strengthened by the observation that GF withdrawal-
induced phosphorylation takes place in several species, mouse and human, and is not 
confined to one cell type.
Figure 6.6. IL-3 depletion induces the formation 
of specific MG-derived AGEs in Ba/F3 cells.
A. Formation of specific MG-AGEs. Ba/F3 cells were 
depleted of IL-3 and lysed in CEB after indicated 
periods of time. Equal amounts of protein were 
separated by SDS-PAGE and transferred onto PVDF 
using electrotransfer. Formation of specific MG-AGEs 
was analysed using the mAB6B antibody (Biologo). 
As a loading control, blots were subsequently stripped 
and reprobed with a β-actin antibody (Abcam). B. 
Inhibition of MG-AGE formation. Ba/F3 cells were 
depleted of IL-3, cultured in the presence of LiCl or 
Z-VAD-FMK and lysed in CEB after indicated periods 
of time. Equal amounts of protein were separated 
by SDS-PAGE and transferred onto PVDF using 
electrotransfer. Formation of specific MG-AGEs was 
analysed using the mAB6B antibody. As a loading 
control, blots were subsequently stripped and 
reprobed with a β-actin antibody.
Figure 6.7. MG is synergistic with IL-3 depletion-
induced apoptosis.
A. Cell death with exogenous MG. Ba/F3 cells 
were washed in culture medium without IL-3 and 
subsequently cultured in the presence or absence 
of IL-3 and MG was added. After 24 hours apoptosis 
was measured by the analysis of the percentage of 
cells with sub-diploid DNA. B. and C. Inhibition of 
cell death. Ba/F3 cells were depleted of IL-3 and 
cultured in the presence of MG and LiCl (B) or NAC 
(C). After 24 hours apoptosis was measured by the 
analysis of the percentage of cells with sub-diploid 
DNA. Concentrations used are LiCl: 20 mM, NAC: 
20 mM, MG: 500 µM.
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GSK-3 is involved in IL-3 starvation-induced post-translational modification of 
GLO1.
 GSK-3 has been shown to have a central role in the regulation of cell cycle and 
apoptosis (43,44). Also, upon  growth factor withdrawal, GSK-3 is involved in the induction 
of G1 arrest by regulating the levels of cyclin D1 (62,63), and in the induction of apoptosis 
and inhibition of GSK-3 activity also ameliorates the growth factor-withdrawal-induced cell 
death (45-48,64). To investigate whether GSK-3 was involved in the phosphorylation of 
GLO1 upon IL-3 depletion of Ba/F3 cells, we used LiCl, a well known inhibitor of GSK-3 
(65). Because it has been previously shown that activation of GSK-3β is required for the 
induction of apoptosis by GF-depletion, we first tested in our experimental setting whether 
inhibition of GSK-3β by LiCl also inhibited apoptosis in Ba/F3 induced by depletion of IL-
3. Ba/F3 cells were cultured with or without conditioned WEHI-3B medium as a source 
of IL-3, and in the presence or absence of LiCl. As expected, LiCl inhibited apoptosis by 
approximately 80% induced by IL-3 depletion (Figure 6.3.A). Next, we examined whether 
LiCl had an effect on the phosphorylation of GLO1 induced by IL-3 depletion from Ba/F3 
cells. As shown in Figure 6.3.B, the phosphorylation of GLO1 (indicated by an arrow) was 
completely prevented in the presence of LiCl. In addition, the phosphorylation of GLO1 
induced by depletion of IL-3 was also completely prevented in the presence of a more 
specific inhibitor of GSK-3β namely SB216763 (Figure 6.3.C). SB216763 also inhibited 
apoptosis induced by IL-3 starvation to the same extent as LiCl (Figure 6.3.A). These 
results indicate that GSK-3β is involved in the pathway that leads to phosphorylation of 
GLO1 induced by IL-3 starvation. It is however unlikely that GLO1 is a direct substrate for 
GSK-3β, because coexpression of the catalytic subunit of GSK-3β with GLO1 in serum-
starved HEK293 cells did not result in phosphorylation of GLO1 as studied by means of 
labelling cells with 32P-orthophosphate. Nor could GSK-3β phosphorylate GLO1 in vitro 
(see chapter 7). By contrast, coexpression of the catalytic subunit of CaMKII with GLO1 
in HEK293 did result in phosphorylation of GLO1 (de Hemptinne and Vancompernolle, 
unpublished results) and GLO1 is also an in vitro substrate for CaMKII (see chapter 7).
Methylglyoxal detoxification is not impaired after IL-3 depletion
 Given the cytostatic and cytotoxic properties of MG, a likely hypothesis could be that 
upon IL-3 depletion, the MG-detoxification capacity of the GLO system could be inhibited 
by for instance phosphorylation of GLO1. This would cause a rise in the intracellular MG 
concentration, a condition that could induce growth arrest and if the absence of IL-3 
persists, ultimately apoptosis. To investigate whether the MG-detoxification capacity of the 
glyoxalase system was impaired upon IL-3 depletion, we measured GLO1 activities as 
well as D-lactate concentrations, the end product of the glyoxalase system. The formation 
of D-lactate was measured by a fluorimetric enzyme assay as described in (53). The 
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concentration of D-lactate was determined by the formation of NADH during oxidation of 
D-Lactate by D-lactate dehydrogenase. As shown in Figure 6.4.A, there is no significant 
difference in formation of D-lactate between IL-3 starved cells and control cells. GLO1 
activity in cell lysates derived from Ba/F3 cells in the presence or absence of IL-3 was 
determined by a spectrophotometric method, which monitors the initial rate of the GLO1-
catalyzed production of S-D-lactoylglutathione from the hemithioacetal that is formed 
spontaneously by incubating MG in glutathione (see M&M). As shown in Figure 6.5.A, 
in several separate experiments there was no significant change in GLO1 activity in cell 
lysates from IL-3-depleted cells compare to control cells. These findings indicate that the 
MG-detoxification activity of the glyoxalase system is not altered upon GF withdrawal. These 
data also suggest that phosphorylation of GLO1, which is induced upon GF withdrawal, is 
not accompanied by changes in the GLO1 activity, which is in agreement with our previous 
findings in L929 cells (24). This finding is further strengthened by the observation that 
inhibition of GLO1 phosphorylation with LiCl or SB216763 upon IL-3 depletion, did not 
result in a change of the D-lactate production or the in vitro GLO1 activity (Figure 6.4.B and 
6.4.C, and Figure 6.5.B respectively).
Specific MG-derived AGEs are formed during IL-3 withdrawal.
 MG has been reported to be involved in several signaling pathways (24,66-69). 
Recent findings indicate MG has a distinct role as a modulator of cell death (24,70-72). 
Previous results indicated that phosphorylated GLO1 was involved, directly or indirectly, in 
a pathway that leads to MG-derived AGE modification of specific proteins. Therefore, we 
tested whether MG-derived AGE modification was also induced upon GF withdrawal. For 
this purpose, we used a monoclonal antibody (mAb6B) raised against in vitro MG-modified 
keyhole limpet hemocyanin. This antibody recognizes MG-modified proteins in arterial 
walls of diabetic kidneys (73) and we have previously shown that this antibody recognizes 
specific MG-derived AGE epitopes induced during TNF-induced cell death in L929 cells 
(24). A Western blot of cell lysates derived from IL-3 depleted Ba/F3 cells developed with 
this antibody is shown in Figure 6.6.A. MG-derived AGE modification is induced on a 
distinct protein band, with an apparent M.W. 16 kDa (indicated by an arrow), after 22h of 
IL-3 depletion. The MG-derived AGE formation was already observed after eight hours of 
IL-3 starvation (data not shown).  
 Next, we investigated whether phosphorylated GLO1 was involved in the induction 
of MG-derived AGE-modification of the 16 kDa protein. As already shown in Figure 6.3, 
inhibition of GSK-3 by LiCl efficiently inhibited the phosphorylation of GLO1, therefore 
we used LiCl to test whether inhibition of GSK-3 also influenced the MG-derived AGE-
formation. As shown in Figure 6.6.B, MG-derived AGE-modification of the 16 kDa protein 
(indicated by an arrow) was significantly reduced in the presence of LiCl. 
 Since GF-withdrawal also induces caspase activation (74), we also tested the 
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Figure 6.8. Activation of p38 by exogenous MG.
A. Activation of p38. Ba/F3 cells were washed in culture medium without IL-3 and subsequently cultured in 
the presence or absence of IL-3 and MG was added. Cells were lysed in CEB after indicated periods of time. 
Equal amounts of protein were separated by SDS-PAGE and transferred onto PVDF using electrotransfer. 
Activation of p38 was determined using an antibody directed against phosphor-p38 (Cell Signaling). 
Subsequently blots were stripped and reprobed with an anti-p38 antibody (Cell Signaling). B. Inhibition of p38 
activation. Ba/F3 cells were depleted of IL-3 and cultured in the presence of MG and LiCl or NAC. Cells were 
lysed in CEB after indicated periods of time. Equal amounts of protein were separated by SDS-PAGE and 
transferred onto PVDF using electrotransfer. Activation of p38 was determined using an antibody directed 
against phosphor-p38. Subsequently blots were stripped and reprobed with an anti-p38 antibody. C. MG-
dependent cell death. Ba/F3 cells were depleted of IL-3 and MG and SB203580 were added. After 24 hours 
apoptosis was measured by the analysis of the percentage of cells with sub-diploid DNA. Concentrations 
used are LiCl: 20 mM, NAC: 20 mM, MG: 500 µM and SB203580: 10 µM. Protein band intensities were 
measured using Genetools software (Westburg) and phosphor-p38 to p38 ratios were determined.
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possibility whether the 16 kDa MG-AGE-modified protein was formed by caspase-cleavage 
of a larger pre-formed MG-AGE-modified protein. As shown in Figure 6.6.B, the 16 kDa 
MG-AGE-modified protein was still formed in the presence of the pan-caspase inhibitor Z-
VAD-FMK. 
Exogenous MG reinforces the induction of apoptosis after IL-3 withdrawal
 To further examine whether MG played a role in the induction of apoptosis in Ba/
F3 cells induced by IL-3 depletion, we tested the effect of exogenously added MG. The 
percentage of apoptotic cells was measured by flow cytometry using the percentage of 
cells that had a hypoploid DNA profile (expressed as sub-G1). As shown in Figure 6.7.A, in 
the presence of 0.5 mM exogenously added MG and in the absence of IL-3, the percentage 
of apoptotic cells was increased by approximately 55 % compared to the percentage of 
apoptotic cells induced by IL-3 depletion alone. As a control, addition of 0.5 mM MG did 
not induce apoptosis in a Ba/F3 cell culture in the presence of IL-3. In the presence of IL-3, 
exogenous addition of 0.5 mM MG could also not induce formation of the specific 16 kDa 
MG-AGE-modified protein (data not shown).
We next sought to determine whether GSK-3β was involved in this synergistic effect 
induced by exogenous MG. As shown in Figure 6.7.B, the synergistic effect by exogenous 
MG (0.5 mM) on the induction of apoptosis induced by IL-3 depletion was completely 
abolished in the presence of LiCl. Moreover, addition of LiCl also prevented the synergistic 
effect on the formation of the specific 16 kDa MG-AGE-modified protein (data not shown). 
These data suggest that GSK-3β plays a crucial role in this process and that the role of MG 
and presumably the specific MG-derived AGE-modified proteins is downstream of GSK-
3β.
   Effects of MG on cells are often dependent on the formation of reactive oxygen 
species (ROS; (15,16,21,75-78)). Even though the reaction of MG with amino acids by itself 
leads to superoxide formation (79-81), MG also hampers the activities of the antioxidant 
mechanisms in cells (21,82-84) and directly modifies components of respiratory complex 
III in mitochondria, the major site of superoxide production (85,86). In order to investigate 
the role of ROS in the induction of apoptosis, the effect of N-acetyl-cysteine (NAC) was 
examined on IL-3 starvation and MG-induced apoptosis. Co-incubation of Ba/F3 cells with 
NAC strongly impedes the outcome of addition of MG on apoptosis (Figure 6.7.C).
MG-induced effects are not mediated by the p38 MAPK pathway
 Several reports implicate the p38 and JNK MAPK pathways in MG-induced signaling 
to cell death. MG induces a rise in intracellular ROS, hereby leading to the activation of 
apoptosis signal-regulating kinase 1 (ASK1), and subsequently the p38α MAPK pathway 
(20). When Ba/F3 cells are deprived of IL-3 in the presence of MG, a strong and rapid 
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phosphorylation of p38 is induced (Figure 6.8.A). A time-course experiment shows that 
p38 is phosphorylated within 0.5 hour and peaks after 2 hours. Together with the induction 
of phosphorylation, an increase in the total amount p38 is also observed. But when the 
ratios of phosphorylated p38 to total p38 are calculated it is clear that the rise in activated 
p38 is mainly caused by phosphorylation. However, also in the presence of IL-3 addition of 
MG leads to a strong activation of p38 (Figure 6.9.A), although MG is not cytotoxic at the 
concentration used (Figure 6.7.A). This suggest that exogenous MG is able to activate p38 
MAPK independent of when IL-3 is present or not.
 Next, we tested whether the GSK-3β inhibitor LiCl could prevent the phosphorylation 
of p38 induced by MG. As shown in Figure 6.8.B, this was not the case although LiCl 
strongly abrogates the induction of apoptosis by MG. In contrast, NAC could prevent 
the MG-induced phosphorylation of p38 and also MG-induced cell death (Figure 6.7.C 
and Figure 6.8.B). Next, we used a specific p38 MAPK inhibitor SB203580, to examine 
whether p38 played a role in the synergistic effect of MG on the induction of apoptosis. 
Pre-incubation with SB203508 had no significant effect on MG-induced cell death (Figure 
6.8.C). Of note is the observation that NAC by itself is able to induce p38 phosphorylation 
to a certain degree (Figure 6.8.B). This might be a consequence of the observed pro-
oxidant activity of NAC under certain conditions (87). In summary, these data suggest that 
the synergistic effect of MG on the induction of apoptosis induced by IL-3 depletion occurs 
independent of p38 MAPK, but is dependent on GSK-3β.
DISCUSSION
 MG is a by-product of glycolysis, the most fundamental metabolic pathway. It 
therefore occurs in every cell and despite the presence of several detoxifying mechanisms 
Mg can reach high intracellular levels (88). Approximately 10% of total protein content has 
been estimated to be modified by MG under physiological conditions. Previous reports 
from our group have implicated MG in TNF-induced necrosis (24). GLO1 is phosphorylated 
in a PKA-dependent manner and a concomitant rise in MG is observed. As a consequence 
of these events specific MG-derived AGEs are formed. Inhibition of these events efficiently 
provides protection against TNF-induced necrosis in L929 cells.
 In this study we have demonstrated that depletion of IL-3 induces phosphorylation 
of GLO1. A possible kinase to be involved in this process would be GSK-3β. GSK-3β is a 
ubiquitously expressed serine/threonine kinase and is a key regulator in diverse biological 
processes, including regulation of metabolism and apoptosis (reviewed in (43,44)). A 
remarkable characteristic of this kinase is the fact that it GFs lead to its inactivation by 
phosphorylation, and that inactivation of GSK-3β is correlated with survival whereas 
activation correlates with apoptosis (89,90). Inhibition of GSK-3β with LiCl or the specific 
inhibitor SB216763 also inhibits phosphorylation of GLO1 (Figure 6.3), showing the 
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involvement of GSK-3β. The phosphorylation of GLO1 does not seem to influence the 
activity of GLO1 as measured in vitro nor is there a change in detoxification of MG as 
determined by the production of D-lactate (Figure 6.4 and 5). In spite of the unaltered 
capacities of GLO1 to detoxify MG, specific MG-AGEs are formed. We hereby provide a 
possible physiological function for the ubiquitous GLO system and its primary substrate 
MG. Mammalian cells are dependent on GFs for growth and survival (91). An important 
mechanism used by GFs is the maintenance of cellular metabolism and glycolysis in 
particular (41,42,92,93). The intracellular concentration of MG is determined by the rate 
of glycolysis, and could therefore function as a signal molecule to elicit a response when 
drastic changes occur in the rate of glycolysis, since this would be reflected in intracellular 
MG concentration. IL-3 depletion would indeed induce a rapid decline in glycolysis 
(42,94). 
 Since in vivo induced MG-AGEs are heterogeneous, the choice of the antibody was 
based on the proven efficacy of the antibody to detect argpyrimidine in immunohistochemical 
samples of diabetic patients (73). The specific nature of the MG-derived AGEs was 
substantiated by the observation that addition of exogenous MG was insufficient to induce 
their formation (Figure 6.6.C). Only after IL-3 depletion MG-AGEs were detected, but this 
could be inhibited by inhibition of GSK-3β and the consequent phosphorylation of GLO1. 
This strongly supports the hypothesis that both phosphorylated GLO1 and a rise in MG 
levels are required for the formation of specific MG-derived protein modification.
 MG is known to be a strong inducer of ROS and this ROS formation is often implied 
in the detrimental activity of MG (15,16,21,77,85). We also found the synergy of MG with 
IL-3 depletion could be abrogated by addition of NAC, an anti-oxidant which has been 
shown to be able to quench MG-induced ROS production (76). The concentrations of MG 
used in this report are within the range commonly used when the biological effects of MG 
are studied (19,21,75,85,95,96). Moreover, MG levels do not exceed the levels found in 
living cells (88), and are not cytotoxic by themselves (Figure 6.7.A). Several studies show 
the p38 and JNK MAPK pathways are activated upon MG-induced ROS formation and 
mediate the subsequent signaling events (15,16,20,75,95). However, this doesn’t seem 
to be the case in our system. Although a strong activation of p38 was induced by MG, this 
was not sufficient to induce cell death (Figure 6.8). Nor could it be inhibited by LiCl, even 
though this strongly inhibited cell death and MG modification of protein. This observation 
is even strengthened by the inability of the specific p38 inhibitor SB203580 to inhibit the 
synergistic effect seen between IL-3 starvation and exogenous MG. Phosphorylation of 
JNK was also observed, but to a much lesser extent than p38 activation (data not shown). 
Further examination of the specific MG-modified protein or the possible pathways activated 
by ROS are needed to clarify the action of MG and phosphorylated GLO1 in IL-3 depletion-
induced apoptosis.
 In conclusion this report shows that upon IL-3 depletion in Ba/F3 cells GLO1 is 
phosphorylated in a GSK-3β dependent manner. Subsequently specific MG-modification 
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of proteins occurs. The formation of these MG-modified proteins is not the consequence 
of a simple rise in intracellular MG concentrations, since neither GLO1 activity or MG 
detoxification is impaired, nor could they be induced by addition of exogenous MG. Our 
results could provide a system that allows cells to integrate external signals from GFs with 
metabolism.
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Chapter 7: Glyoxalase I is a direct substrate for Ca2+/Calmodulin 
Dependent Kinase II (CaMKII)
INTRODUCTION
 
 Despite the ample research on the glyoxalase (GLO) system and GLO1 in particular, 
most of the focus has been on the expression levels and activity, and relatively little is 
known about posttranslational modification. For human GLO1 it has been described that 
NO, in cooperation with glutathione, is able to induce modification of GLO1, resulting in a 
decreased activity and an isoelectric shift towards the basic end on two-dimensional gels 
(1,2). Similar effects have been described later to occur in yeast and in vitro as well (3). 
Phosphorylation has been described in yeast (4) and mammalian cells ((5,6); chapters 6 
and 8 of this thesis), and in plants as well (7,8). Although several different kinases, such 
as PKA (5,6),GSK-3β (chapter 6) and the PI3K/Akt/mTOR pathway (see chapter 8), have 
been shown to be involved in the phosphorylation of GLO1 in mammalian cells, to date, it 
has not been described which kinase can directly phosphorylate GLO1.
 
 In Arabidopsis, GLO1 was found to be phosphorylated upon overexpression of 
SNF1-related protein kinase 2.8 (SnRK2.8 (8)). In vitro kinase assays shows that SnRK2.8 
directly phosphorylated GLO1 and a concomitant increase of GLO1 activity was found 
upon phosphorylation. The SnRK family members are the plant homologues of AMPK 
(AMP-activated protein kinase) and play a broad role in growth and metabolic responses 
to cellular stress (9). Quite interestingly, SnRK2.8 has been shown to be important in the 
response to drought and salinity (10), a property shared with GLO1 (11-13). Also, in rice leaf, 
GLO1 was identified as a phosphoprotein (7). Phosphorylation was induced by gibberellin, 
which is known to be an important regulator of cell growth, and was mediated by a putative 
54-kDa Ca2+ dependent protein kinase (CDPK). Furthermore it was shown earlier that Ca2+ 
and calmodulin (CaM) were involved in light-mediated GLO1 activity in plants (14,15) and 
inhibitors of CaM showed an inhibitory effect on GLO1 activity (16). The data presented 
in this chapter provide evidence for the phosphorylation of mammalian GLO1 by Ca2+/
calmodulin-dependent kinase II (CaMKII). Of note is also the shared consensus sequence 
for phosphorylation among CaMKII (17) and SnRK2.8 (18,19).
 The goal of this study was to find the kinase that directly phosphorylates GLO1. 
Our data demonstrate that GLO1 is a direct substrate for CaMKII in vitro, and CaMKII is 
able to phosphorylate GLO1 in vivo. We could however not yet establish a role for CaMKII 
in GLO1 phosphorylation induced by IL-3 starvation of Ba/F3 cells, as KN-93, a specific 
inhibitor for CaMKII, was unable to inhibit IL-3 induced apoptosis. 
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RESULTS AND DISCUSSION
GLO1 is phosphorylated upon coexpression with GSK-3β in Hek293 cells
 
As described in chapter 6 of this thesis, we showed earlier that inhibition of GSK-3β 
inhibited the phosphorylation of GLO1 which is induced by IL-3 starvation of Ba/F3 cells. 
To further study the phosphorylation of GLO1, we cotransfected Hek293 cells with an 
expression vector encoding wild type GLO1 and a vector containing GSK-3β. Cells were 
lysed 24 hours after transfection and phosphorylation was examined by 2-dimensional 
electrophoresis (2-DE) using an antibody raised against rabbit GLO1. Overexpression of 
GLO1 in itself already induced multiple phosphorylations, as shown by the many isoforms 
observed in Figure 7.1.A (middle panel; the non-phosphorylated, non-NO-responsive form 
is designated as the α-isoform). However, when GLO1 was cotransfected with a GSK-
3β cDNA, a strong phosphorylation was induced on the NO-responsive isoforms (Figure 
7.1.A, indicated with an arrow). Subsequently the same cotransfection was performed as 
described, but 24 hours after transfection the serum was depleted for 2 hours before cell 
lysis in order to fully activate GSK-3β and further mimic the conditions from chapter 6. Under 
these conditions, however, GSK-3β only showed a minor effect on the phosphorylation of 
the NO-responsive isoform of GLO1 (Figure 7.1.B; indicated with an arrow). 
CamKII phosphorylates GLO1 in vitro
 Next, we studied whether GLO1 is a direct substrate for GSK-3β. Analysis of 
the amino acid sequence shows the presence of the typical GSK-3β consensus site 
(consecutive Ser/Thr residues, separated by three amino acids), with Ser94 and Thr98 
being the potential sites for phosphorylation by GSK-3β. This site is located at the interface 
of the GLO1 dimer and is conserved between human and mouse (Figure 7.2.A; the GSK-
3β consensus site is underlined; for more information about potential phosphorylation sites 
see also supplementary figure page 114). We therefore performed in vitro kinase assays 
using purified recombinant GLO1 from E. coli. However, as shown in figure 7.2.B, we were 
unable to detect phosphorylation of GLO1 by GSK-3β in vitro.
 The consensus sequence for GSK-3β phosphorylation however includes a serine or 
threonine residue that is already phosphorylated (primed) by another kinase (S/T-X-X-X-
phospho-S/T) (20). Analysis of the amino acid sequence from GLO1 reveals the presence 
of a predicted CaMKII consensus site at Thr98 ((R-X-X-S/T) (17); Figure 7.2.A; indicated by 
a box) . This CaMKII consensus site overlaps with the predicted consensus site for GSK-3β 
and could therefore serve as a priming site for GSK-3β. Of note, the CaMKII consensus 
site is identical to the consensus site for the plant kinase SnRK2.8, which has been shown 
to be a direct kinase for GLO1 in Arabidopsis (8).
 To evaluate whether CaMKII could phosphorylate GLO1 we first performed in vitro 
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Figure 7.1. Coexpression of GLO1 with GSK-3β.
A. Coexpression of GLO1 with kinases in Hek293 cells. Hek293 cells were cotransfected with expression 
vectors encoding GLO1 and expression vectors containing GSK-3β. Cells were lysed in CEB after 24 hours 
and after ethanol precipitation resuspended in 2-DE lysis buffer. Protein concentrations were determined and 
10 µg of the lysates was loaded for separation by 2-dimensional gel electrophoresis (pH 4-7). Representative 
western blots of 2-DE gels developed with a polyclonal anti-human GLO1 antibody are shown. A reference 
spot α, which corresponds to the non-NO-responsive form of GLO1 is indicated (5). B. Coexpression of 
GLO1 with kinases in serum-starved Hek293 cells. Hek293 cells were co-transfected with expression vectors 
encoding GLO1 and expression vectors containing GSK-3β. 24 hours after transfection cells were depleted of 
serum for 2 hours. Cells were lysed in CEB and after ethanol precipitation resuspended in 2-DE lysis buffer. 
Protein concentrations were determined and 10 µg of the lysates was loaded for separation by 2-dimensional 
gel electrophoresis (pH 4-7). Representative western blots of 2-DE gels developed with a polyclonal anti-
human GLO1 antibody are shown. 
kinase assays using purified recombinant GLO1 from E. coli. When recombinant GLO1 
was incubated in reaction buffer alone in the presence of 32P-ATP, no phosphorylation 
could be observed (Figure 7.3.A). The presence of contaminating kinases or a possible 
autophosphorylation activity could thus be excluded. Coincubation of GLO1 with activated 
CaMKII, on the other hand, clearly induced phosphorylation (Figure 7.3.A). 
 We subsequently overexpressed and purified GLO1 from Hek293 cells for in vitro 
kinase assays. As shown in Figure 7.3.B, purified GLO1 from Hek293 cells could also 
be efficiently phosphorylated by CaMKII in vitro. Of note is the appearance of a high 
molecular weight band on the autoradiograph (indicated by a white arrowhead). Overlay 
of the autoradiograph with a Western blot performed with an anti-GLO1 antibody however 
revealed this represents a GLO1-dimer. Mammalian GLO1 requires dimerization for its 
activity (21) and this dimer is known to be extremely stable and highly resistant against 
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reducing conditions (22). These results suggest that phosphorylation does not inhibit 
dimerization. Inhibition of dimerization would lead to inactivation of GLO1 (21,23,24). 
 The in vitro phosphorylation assays described above were performed on GLO1 which 
was purified using hexyl-glutatione linked beads and subsequently eluted using 10 mM s-
hexylglutathione, dissolved in CaMKII reaction buffer. However, for the required sequential 
phosphorylation reactions, the priming with CaMKII and the phosphorylation with GSK-3β, 
the phosphorylation activity of the first kinase needs to be eliminated. This can be achieved 
by heat inactivation of the enzyme. Alternatively, GLO1 which is still bound to the hexyl-
glutathione beads, can be used for the in vitro assays, with the advantage that the first 
kinase can be washed away. An additional benefit would be the possibility to use different 
reaction buffers for the sequential reactions. We therefore tested an alternative protocol to 
examine whether GLO1 which was bound to beads could also serve as a substrate for our 
assays.
 When protein-loaded beads were coincubated with activated CaMKII, GLO1 was 
phosphorylated by CaMKII (Figure 7.3.C left panel). This demonstrates that the binding 
of GLO1 to beads does not interfere with phosphorylation. Of note, when lysis buffer in 
which phosphatase inhibitors were omitted was used to lyse cells and wash the beads, 
phosphorylation of GLO1 by CaMKII could further be enhanced, most likely because any 
phosphorylation that might have occurred in the cells was removed or reduced (Figure 
Figure 7.2. GLO1 is no direct target for GSK-3β in vitro.
A. Kinase consensus sequences. Alignment of the sequence of human and mouse 
GLO1 shows the presence of the conserved consensus sequences for GSK-3β (S/T-X-
X-X-phospho-S/T; underlined) and CaMKII phosphorylation (R-X-X-S/T; box). Potential 
targets for phosphorylation are indicated in bold (phosphorylation sites are determined 
using Netphos software). B. Recombinant GLO1 is not phosphorylated by GSK-3β. 
2 µg of recombinant GLO1 was incubated with GSK-3β as described in methods. 
Phosphorylation was detected by autoradiography, followed by western blot with an 
anti-GLO1 antibody.
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Figure 7.3. GLO1 is a direct substrate for CaMKII in vitro.
A. Recombinant GLO1 is phosphorylated by CaMKII. 2 µg of recombinant wild type GLO1 was incubated 
with activated CaMKII as described in methods. Phosphorylation was detected by autoradiography, followed 
by western blot with an anti-GLO1 antibody. B.  Purified GLO1 from Hek293 is phosphorylated with CaMKII. 
Hek293 cells were transfected with expression vectors containing wild type GLO1. After 24 hours, transfected 
cells were lysed in CEB and GLO1 was purified as described in methods. Purified GLO1 was subsequently 
incubated with activated CaMKII. Phosphorylation was detected by autoradiography, followed by western 
blot with an anti-GLO1 antibody. Momomer GLO1 is indicated with a black arrowhead, dimer GLO1 is 
indicated with a white arrowhead. C. GLO1-loaded beads are phosphorylated by CaMKII. Hek293 cells were 
transfected with expression vectors containing wild type GLO1. After 24 hours, transfected cells were lysed in 
CEB (left panel) or in CEB without phosphatase inhibitors (right panel) and GLO1 was purified as described 
in methods. Protein-loaded beads were subsequently incubated with activated CaMKII. Phosphorylation was 
detected by radiography, followed by western blot with an anti-GLO1 antibody.
7.3.C right panel).
Subsequently we tested the hypothesis that CaMKII-dependent phosphorylation could 
serve as a priming phosphorylation for GSK-3β. Recombinant GLO1 from E. coli was first 
coincubated with activated CaMKII in the absence of 32P-ATP for 30 minutes. Then CaMKII 
was heat inactivated and the reaction mixture was incubated with GSK-3β, in the presence 
of 32P-ATP. Concomitantly unprimed GLO1 was coincubated with GSK-3β. As shown in 
Figure 7.4.A, no phosphorylation could be observed with GSK-3β, not even when GLO1 
was first primed with CaMKII. However, CaMKII itself significantly phosphorylated GLO1. 
Also when GLO1 was purified from Hek293 cells and GLO1 bound to beads was used 
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for in vitro phosphorylation, no phosphorylation could be observed with GSK-3β (data not 
shown).
 Another kinase that has been described to be involved in the phosphorylation of 
GLO1 is PKA (5,6). In spite of the presence of several consensus sites in the amino acid 
sequence for PKA (not shown), we were unable to detect in vitro phosphorylation of GLO1 
with PKA (Figure 7.4.B).
Figure 7.4. Primed GLO1 is no direct target for GSK-3β in vitro.
A. Recombinant GLO1 is not phosphorylated by GSK-3β after priming with CaMKII. 2 µg of recombinant 
wild type GLO1 was incubated with activated CaMKII in the absence of 32P-ATP as described. After heath 
inactivation, the samples were incubated with GSK-3β in the presence of 32P-ATP. As a control 2 µg of 
recombinant GLO1 was directly incubated with either activated CaMKII or GSK-3β. Phosphorylation was 
detected by autoradiography, followed by western blot with an anti-GLO1 antibody. B. Recombinant GLO1 is 
not phosphorylated by PKA. 2 µg of recombinant GLO1 was incubated with PKA as described in methods. 
Phosphorylation was detected by autoradiography, followed by western blot with an anti-GLO1 antibody.
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Involvement of CaMKII in IL-3 depletion-induced apoptosis
 To asses whether CaMKII was involved in IL-3 starvation-induced apoptosis, Ba/
F3 cells were depleted of IL-3 in the presence of KN-93, a specific inhibitor of CaMKII. 
Apoptosis was subsequently determined by measuring DNA breakdown. However, 
inhibition of CaMKII had no effect on apoptosis induced by IL-3 depletion (Figure 7.5).
CONCLUSIONS
 Although the GLO system has been discovered almost a hundred years ago, the 
only known function is the detoxification of reactive α-oxoaldehydes (25). Identification of 
the kinases involved in the modification of GLO1 might shed a light over the precise role 
of the GLO system. GLO1 has been shown to be phosphorylated in mammals, plants and 
in yeast (5-8,26). In spite of the involvement of several signaling pathways, to date, the 
kinase responsible for the phosphorylation of GLO1 has not been described in mammals. 
In Chapter 6 it was described how inhibition of GSK-3β also inhibited the IL-3 depletion-
induced phosphorylation of GLO1. These observations were corroborated here by the 
observation that coexpression of GLO1 with GSK-3β also induces phosphorylation of 
GLO1. On the other hand, in vitro phosphorylation assays revealed that GLO1 is no direct 
substrate for GSK-3β. However, our data shows that GLO1 is a direct substrate for CaMKII. 
Although the predicted consensus sites for CaMKII and GSK-3β seem to overlap, CaMKII 
does not seem to be a priming kinase for GSK-3β phosphorylation. It can not be ruled out 
however that GSK-3β can directly phosphorylate GLO1, but that there is a different priming 
kinase.
Figure 7.5. Inhibition of CaMKII does not inhibit IL-3 starvation-
induced apoptosis.
Effect of CaMKII inhibition on IL-3 depletion-induced apoptosis. Ba/F3 
cells were depleted of IL-3 and KN-93 (10 µM) was added. Apoptosis 
was measured by the analysis of the percentage of cells with sub-
diploid DNA at the indicated time points.
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 CaMKII is a ubiquitously expressed kinase family, which needs Ca2+ and calmodulin 
for its activation (27). CaMKII is involved in a wide range of cellular processes, among 
which cell growth and division (28-30), and cell death (28-31), making it a likely candidate 
to be involved in TNF-induced necrosis and IL-3 starvation-induced apoptosis. However, 
inhibition of CaMKII did not exert an effect in the induction of apoptosis induced by IL-3 
depletion of Ba/F3 cells. Nevertheless, the involvement of CaMKII in the phosphorylation of 
GLO1 in vivo was demonstrated in TNF-induced necrosis in the mouse fibroblast cell line 
L929 (de Hemptinne et al., in preparation). 
 CaMKII is probably not the only kinase capable of phosphorylating GLO1. From 
the 2-DE pattern of GLO1 it could be concluded that, for instance TNF can induce multiple 
phosphorylations of GLO1 (5). Further research is therefore still needed to fully elucidate 
all the kinases involved in modification of GLO1.
MATERIALS AND METHODS
Cell Lines and Cultures 
 The IL-3 dependent pro-B cell line Ba/F3 (32) was purchased from DSMZ. Ba/
F3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with glutamax 
(Invitrogen) supplemented with heat-inactivated FBS (10% v/v) (Cambrex), penicillin 
(100 units/ml) and streptomycin (0.1 mg/ml) and 5% conditioned medium from WEHI-
3B cells as a source of mouse IL-3. Ba/F3 cells were cultured at 37°C in a humidified 
incubator under an 5% CO2 atmosphere. Hek293 cells, were cultured in DMEM with 
glutamax (Invitrogen) supplemented with heat-inactivated FBS (10% v/v), penicillin (100 
units/ml) and streptomycin (0.1 mg/ml) at 37°C in a humidified incubator under an 8% CO2 
atmosphere.
Cell stimulations
IL-3 was removed by washing exponentially growing cells 3 times in culture medium 
without conditioned WEHI-3B medium and resuspended in culture medium in the absence 
or presence of conditioned WEHI-3B.
Chemicals and inhibitors used are KN-93 (calbiochem). Duration and concentrations 
used as described.
 Hek293 cells were transiently transfected by Ca precipitation. Vectors used are 
pCAGGS vectors containing wild type GLO1 and an expression vector for GSK-3β, kindly 
donated by Dr Jim Woodgett (Department of Medical Biophysics, Samuel Lunenfeld 
Research Institute, Toronto, Ontario, Canada).
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DNA distribution analysis
 Cells were stained with propidium iodide (PI, Sigma) containing staining solution 
(33) and analyzed by a FACSCalibur flow cytometer (488Ex/590Em). Cell Quest software 
was used to analyze cell cycle distribution (FACS Calibur, Becton Dickinson) (33,34). Ten 
thousand cells were routinely analyzed.
Electrophoresis and immunoblotting
The cells were washed 3 times with ice-cold PBS buffer and lysed with cytosol 
extraction buffer (10 mM Tris-HCL pH7.4, 50 mM EDTA pH8.0, 25 mM NaCl, 0,7% 
TritonX-100, 100 mM PMSF, 1 tablet Complete Protease Inhibitor Cocktail (Roche)/50 ml 
cytosol extraction buffer). Cell lysates were cleared by centrifugation (14,000 x g). Protein 
concentrations were determined using Bradford method. Proteins were separated by 
SDS-PAGE and transferred onto a PVDF membrane (Hybond-P, Amersham Pharmacia 
Biotech). The blots were incubated with the desired antibodies followed by ECL-based 
detection (Amersham Pharmacia Biotech).
2-Dimensional Gel Electrophoresis 
Isoelectric focusing was carried out on 18 cm IPG strips, pH 4-7 (GE Healthcare) 
according to the manufacturer’s instructions. For the second dimension, proteins were 
separated by SDS-polyacrylamide gel electrophoresis (PAGE, 12%).
Recombinant expression and purification of GLO1 in E. coli
 Wild type GLO1 was subcloned into pGEX-6P-1 GST fusion vector (Amersham 
Pharmacia Biotech) and wild type GLO1 was purified according to manufacturers 
instructions. Protein concentrations were determined using using Bradford method. 
Aliquots were stored at -80°C until further use. 
 
Purification of GLO1 from Hek293 cells for in vitro phosphorylation
Cell cultures were transfected and lysed as described above. The cell lysates were 
incubated with S-hexylglutathione-agarose beads (Sigma) for 30 minutes. The cell lysates 
were then removed and the beads were washed 4 times with PBS buffer. GLO1 was eluted 
from the beads using 10 mM s-hexylglutathione, dissolved in CaMKII reaction buffer. 
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Phosphorylation reactions
2 µg of recombinant GLO1 or 10 µL of purified GLO1 was incubated with activated 
CaMKII (New England Biolabs), GSK-3β (New England Biolabs) or PKA (New England 
Biolabs) in the respective kinase reaction buffer (New England Biolabs) in the presence 
of 5 µCi 32P-γ-ATP. Reactions were stopped after 1 hour by adding 5x laemmli buffer and 
boiling at 95°C for 5 minutes. 
Alternatively cells were lysed as described above. The cell lysates were incubated 
with S-hexylglutathione-agarose beads for 30 minutes. The cell lysates were then removed 
and the beads were washed 4 times with PBS buffer and twice in kinase reaction buffer. 
Protein-loaded beads were resuspended in kinase reaction buffer and incubated with 
activated CaMKII or GSK-3β in the presence of 5 µCi 32P-γ-ATP at 30°C for 1 hour. 
Reactions were stopped by washing the beads in cytosol extraction buffer containing 
phosphatase inhibitors. Beads were resuspended in 5x laemmli and boiled for 5 minutes. 
The phosphorylated GLO1 was analyzed by SDS-PAGE and autoradiography.
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INTRODUCTION
 
 The glyoxalase (GLO) system is comprised of two enzymes, GLO1 and GLO2. In 
spite of the fact that it has been discovered almost a hundred years ago (1,2), the only 
function conferred to the GLO system is the detoxification of reactive α-oxoaldehydes, 
such as MG (3). The GLO systems ubiquitous nature (4,5), however, suggest a more 
fundamental and conserved role. Moreover, several other enzyme systems exist that are 
capable of detoxifying α-oxoaldehydes (6), rendering the GLO system partially redundant 
for detoxification. Since the work of Albert Szent-Györgyi (5,7-9), the GLO system has 
often been connected to proliferation. A strong correlation has been observed between 
high GLO1 activity and the rate of proliferation (10,11). Elevated levels of GLO1 expression 
or activity have been documented as important for the progression of several tumors and 
have been proposed to be indicative for the enhanced proliferative status (12-20), although 
some reports disprove this (21). Also in plants GLO1 activity strongly correlates with cell 
growth (22-25) and stimulation of cell growth involves an increase in GLO1 activity (26). 
 The availability of growth factors (GFs) is determining in survival, proliferation 
and growth. The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is involved in many 
cellular functions in response to GFs (27-30). A requisite for cell growth and division is the 
presence of glucose and a tight regulation of glucose metabolism (31,32). The involvement 
of the PI3K/Akt signaling pathway in the regulation of glucose uptake and the regulation 
of glycolysis has been well-documented (33-36). An important downstream target by 
which Akt exerts its influence on metabolism is mTOR (37-41). Furthermore, PI3K/Akt/
mTOR signaling also directly regulates GF controlled cell cycle progression, primarily by 
controlling the expression of G1 cyclins (42-45), but also at the end of G2/M (46).
 In order to study the possible role of GLO1 in the regulation of the cell cycle we 
analyzed the phosphorylation of GLO1 during the cell cycle. We show here that during 
progression through the cell cycle different phosphorylations arise. In line with previous 
reports (47), these phosphorylations could not be associated with a change in GLO1 
activity in vitro. Inhibition of the PI3K/Akt partially inhibits the phosphorylation of GLO1. 
Also inhibition of mTOR, one of the downstream targets of the PI3K/Akt pathway involved in 
control of cellular growth, in part inhibits the phosphorylation of GLO1. These data implicate 
the PI3K/Akt/mTOR pathway, an important regulator of cell cycle in the modification of 
GLO1.
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RESULTS
Cell cycle dependent phosphorylation of GLO1
 Previous studies in our group show that most cell types express multiple isoforms of 
GLO1, including a NO-modified form and a non-NO-modified form, which was denominated 
the α-isoform (48). These different forms of GLO1 can be multifariously phosphorylated on 
the α-isoform as well as on the NO-modified form. These changes in isoform pattern can 
easily be studied using 2-dimensional gel electrophoresis (2-DE) and immunoblotting with 
an anti-GLO1 antibody (48). Phosphorylation has been shown to yield a shift of the isoform 
to the acidic side of the gel, whereas NO-induced modification results in a shift to the basic 
side.
Figure 8.1. Cell cycle dependent phosphorylation GLO1.
GLO1 was phosphorylated during G1 (A) and at G1/S transition (B). Ba/F3 cells were synchronized by IL-3 
starvation over night. Cell cycle was induced by re-addition of IL-3. This time point was designated 0 hours. 
Cells were lysed in CEB at indicated time points, and after ethanol precipitation resuspended in 2-DE lysis 
buffer. Protein concentrations were determined and 200 µg of the lysates was loaded for separation by 
2-dimensional gel electrophoresis (pH 4-7). Representative western blots of 2-DE gels developed with a 
polyclonal anti-human GLO1 antibody (48) are shown. A reference spot α, which corresponds to the non-
NO-responsive form of GLO1 is indicated (48).  C and D. Analysis of the cell cycle. The different phases of 
the cell cycle were monitored by analysis of the DNA content by flow cytometry. 
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 In Arabidopsis and rice leaf, regulators of cell cycle have been reported to induce 
phosphorylation of GLO1 (49-51). To date, in mammalian cells, no posttranslational 
modifications of GLO1 have been reported in the cell cycle. In chapter 6 we have 
described how GLO1 is phosphorylated during GF withdrawal induced G1 arrest. To study 
phosphorylation during cell cycle, the cell cycle of Ba/F3 cultures was synchronised in the 
G1 phase by IL-3 depletion overnight and subsequently released from this block by re-
addition of IL-3. Cells were lysed 1 hour, 3 hours and 5 hours after re-addition of IL-3 for the 
analysis of the posttranslational modifications of GLO1 in G1 phase using 2-dimensional gel 
electrophoresis (2-DE) (Figure 8.1). Analysis of the DNA-distribution showed Ba/F3 cells 
resided in the G1 phase after all three time intervals (Figure 8.1.C) In lysates made after 
1 hour, only a small number of isoforms is displayed. The α-form could not be observed. 
Instead, the non-NO-modified form is strongly phosphorylated, as can be observed by the 
localisation of the spot more to the acidic side (Figure 8.1.A, upper panel, arrowhead). At 
this time, only a very limited presence of the NO-modified form of GLO1 could be detected. 
In lysates made 3 hours after the release of the cell cycle block, the non-NO-modified 
form of GLO1 is strongly dephosphorylated, as shown in a shift of the spot to the basic 
side. Concomitantly, NO-mediated modification of GLO1 occurs, as witnessed by the 
appearance of a more basic spot (Figure 8.1.A, middle panel, arrow). In the lysates made 
5 hours after the re-addition of IL-3, both the NO-modified form of GLO1 and the non-NO-
modified form of GLO1 were further dephosphorylated (Figure 8.1.A, bottom panel). The 
α-form is now visible.
 Subsequently, we studied the phosphorylation of GLO1 during G1-S transition using 
a same approach (Figure 8.1.B). The percentage of cells in the different phases of the 
cell cycle was determined by analysis of the DNA-distribution on FACS, indicating at the 
chosen time points, cells pass from the G1 phase into the S phase (Figure 8.1.D). Cells 
were lysed 11 hours, 12 hours and 13 hours after the release from G1 arrest. 11 hours after 
the release from G1 arrest, when 65 % of the cells is still in the G1 phase (Figure 8.1.D, black 
bars for the percentage in the G1 phase and white bars for the percentage in the S phase), 
we observed a strong presence of several phosphorylated isoforms on the NO-responsive 
form (Figure 8.1.C, upper panel, arrows). After 12 hours 50 % of the cell population was in 
the G1 phase and 50 % of the cells was in the S phase (Figure 8.1.D). At this time point, a 
hyperphosphorylation of the NO-responsive isoforms could be detected (Fig 1.C, middle 
panel, arrow). After 13 hours, when 70 % of the cells were in the S phase and only 30 % 
still resides in the G1 phase, the NO-responsive form was partially dephosphorylated again 
(Figure 8.1.C, lower panel, arrow). 
 All together, our data shows that GLO1 is strongly modified during the early stages of 
the cell cycle. Both phosphorylation and NO-modification occur. Of note is the observation 
that the G1-S transition coincides with a hyperphosphorylated state of the NO-modified 
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form of GLO1. This hyperphosphorylation is rapidly removed when cells pass on into the S 
phase.
GLO1 activity does not change throughout the cell cycle
 Next, we determined whether the posttranslational modification of GLO1 was 
accompanied by changes in the activity of GLO1. In vitro GLO1 activity in lysates was 
assayed using a spectrophotometric method, which monitors the GLO1-catalyzed 
production of S-D-lactoylglutathione from the hemithioacetal that is spontaneously formed 
when MG is incubated with glutathione (see materials and methods).
 
 Cells were synchronized by overnight IL-3 starvation and subsequent re-addition 
of IL-3. Cell lysates were made after the indicated time intervals after re-addition of IL-3 
and in vitro GLO1 activity was assayed (Figure 8.2.A). The chosen time points are situated 
at the G1-S transition (Figure 8.1.D). Although hyperphosphorylation and consequent 
Figure 8.2. In vitro GLO1 activity is not altered during the cell cycle.
A. GLO1 activity at G1/S transition. Ba/F3 cells were synchronized by IL-3 starvation over night. The cell 
cycle was induced by re-addition of IL-3. This time point was designated 0 hours. Cells were lysed in CEB 
at indicated time points after the re-addition of IL-3, lysates were brought to equal concentrations and cell 
lysates were used to assay GLO1 activity. In vitro GLO1 reaction rates were determined using Ultraspec 
1100 software (Amersham, BD Biosciences) and are shown relative to the reaction rate of lysates made of 
exponentially growing cells, which are set as 100%. B. GLO1 activity in different phases of the cell cycle. G1 
arrest was induced by IL-3 starvation of Ba/F3 cells and G2/M arrest was induced by addition of nocodazole. 
Cells were lysed in CEB, lysates were brought to equal concentrations and cell lysates were used to assay 
GLO1 activity. C. Analysis of the cell cycle. The different phases of the cell cycle were monitored by analysis 
of the DNA content by flow cytometry.
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dephosphorylation of GLO1 can be observed at the G1-S transition (Figure 8.1.C), a 
concomitant change in GLO1 activity could not be observed (Figure 8.2.A). Some fluctuation 
can be noticed in GLO1 activity. However, this was not significant and is probably caused 
by experimental variability.
 In order to further compare GLO1 activity in different phases of the cell cycle, 
we arrested Ba/F3 cells in the G1 phase and in G2/M, respectively by IL-3 depletion or 
addition of nocodazole for 8 hours. Nocodazole inhibits microtubule polymerization and 
blocks mitotic spindle formation, resulting in the accumulation of cells in M. The arrest in 
respective cell cycle phases was verified by analysis of the DNA distribution (Figure 8.2.C). 
Cell lysates were prepared and in vitro GLO1 activity subsequently assayed (Figure 8.2.B). 
Neither G1 arrest or G2/M arrest was accompanied by a change in in vitro GLO1 activity 
when compared to a culture of asynchronously growing cells. 
 We therefore conclude that GLO1 activity as assayed by its ability to catalyze the 
formation of S-D-lactoylglutathione, is not modulated by post-translational modification. 
These results are in line with our previous observations in Ba/F3 cells (chapter 6), but also 
in L929 cells (47) and bovine aortic endothelial cells (BAEC; Laga et al., submitted). Our 
findings however contradict the reported rise in GLO1 activity observed during G2/M in 
carrot cell suspension (52).
Phosphorylation of GLO1 is mediated by the PI3K/Akt pathway
 IL-3 has been shown to induce activation of several signaling pathways, including 
Jak-2/STAT-5, ras/raf/MEK/ERK, and PI3K/Akt kinase cascades (53-55). The PI3K/Akt 
signaling pathway has been implicated in regulating metabolism and  proliferation (56-59). 
We therefore first investigated whether the phosphorylation of GLO1 was dependent on 
PI3K/Akt signaling. 
Ba/F3 cells where synchronized as described previously. 8 hours after the release 
from cell cycle arrest, three dominant spots can be observed. The α-form of GLO1, and two 
more acidic spots. Only little NO-responsive GLO1 is present. 11 hours after re-addition of 
IL-3, the α-form of GLO1 and the middle isoform both are phosphorylated (Figure 8.3.A, 
second panel, black arrowhead and white arrowhead respectively). Also NO-mediated 
modification of GLO1 is induced at that time (Figure 8.3.A, second panel, arrow). One 
hour later, the most acidic spot shifts to the left, indicating this form of GLO1 is subject to 
additional phosphorylation (Figure 8.3.A, third panel, arrowhead), and the phosphorylation 
on the α-form has disappeared again. The NO-responsive form is hyperphosphorylated at 
this time (Figure 8.3.A, third panel, arrow).
However, upon addition of wortmannin, a specific inhibitor for the PI3K/Akt pathway, 
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Figure 8.3. Inhibition of PI3K/Akt interferes with phosphorylation of GLO1 during the cell cycle.
A. Phosphorylation of GLO1 with PI3K/Akt inhibitors. Ba/F3 cells were synchronized by IL-3 starvation over 
night. Cell cycle was induced by re-addition of IL-3. This time point was designated 0 hours. Wortmannin was 
added after 8 hours. Cells were lysed in CEB after indicated time intervals, and after ethanol precipitation 
resuspended in 2-DE lysis buffer. Protein concentrations were determined and 200 µg of the lysates was 
loaded for separation by 2-dimensional gel electrophoresis (pH 4-7). Representative western blots of 2-DE 
gels developed with an anti-GLO1 antibody are shown. Differential spots are indicated with an arrow or an 
arrowhead. B. Effect of PI3K/AKT inhibitors on in vitro GLO1 activity. Ba/F3 cells were synchronized by IL-3 
starvation over night. Cell cycle was induced by re-addition of IL-3. This time point was designated 0 hours. 
Wortmannin was added after 8 hours. Cells were lysed in CEB after indicated time points, lysates were 
brought to equal concentrations and cell lysates were used to assay GLO1 activity. In vitro GLO1 reaction 
rates were determined using Ultraspec 1100  software (Amersham, BDbiosciences) and are shown relative 
to the reaction rate of lysates made of exponentially growing cells, which are set as 100%.
strong inhibition of phosphorylation could be observed. 11 hours after re-addition of IL-3 (and 
three hours after addition of wortmannin), both the phosphorylation on the acidic isoform of 
GLO1 and the phosphorylation on the α-form were severely impaired (Figure 8.3.A, fourth 
panel, black arrowhead and white arrowhead respectively). NO-modification still occurred, 
but the NO-responsive form was phosphorylated to a lesser extent than in the absence of 
wortmannin (Figure 8.3.A, fourth panel, arrow). When the 2-DE pattern of lysates made 
12 hours after initiation of the cell cycle was studied, the hyperphosphorylation of the NO-
modified form of GLO1 was reduced in the presence of wortmannin, when compared to the 
absence of the inhibitor (Figure 8.3.A, fifth panel, arrow). Also the phosphorylation on the 
more acidic isoform was absent (Figure 8.3.A, fifth panel, arrowhead).
Also the in vitro activity of GLO1 was determined. In line with the observations 
discussed above, no differences were observed in the level of GLO1 activity at the G1-
S phase transition and the addition of wortmannin, which did show a drastic effect on 
phosphorylation, did not alter the activity of GLO1 in vitro (Figure 8.3.B).
In order to corroborate our findings in the cell cycle, wortmannin was also added 
to an asynchronous exponentially growing Ba/F3 culture for 3 hours (Figure 8.5.A). 
Whereas a phosphorylation could be observed under control conditions, possibly caused 
by the manipulation of the cells, this was not the case when PI3K/Akt was inhibited with 
wortmannin (Figure 8.5.A, arrowhead). Next, we assayed lysates from asynchronous 
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Ba/F3 cells that were cultured in the presence or absence of wortmannin. In spite of the 
differences in phosphorylation between the different conditions, no change in GLO1 activity 
was induced (Figure 8.5.C).
In summary, our data show that cell cycle dependent phosphorylation of GLO1 
is at least in part dependent on the PI3K/Akt pathway. Our data also strengthens the 
observation that phosphorylation of GLO1 can not be correlated with a difference in in vitro 
GLO1 activity.
Phosphorylation of GLO1 is partially inhibited by rapamycin
 Although inhibition of PI3K strongly influences the phosphorylation status of GLO1, 
phosphorylation of GLO1 still occurs (cf. Figure 8.3.A, fifth panel, where the NO-responsive 
form is still phosphorylated, albeit less). An important downstream target of PI3K/Akt is 
mTOR. mTOR and its target p70S6K1 have been shown to be important mediators of the 
effects of PI3K on cell cycle regulation and proliferation (42,45,60-62). Furthermore, mTOR 
is considered to be a central regulator in cellular growth and is involved in the coordination 
of cell growth with cell cycle (63-65). 
Ba/F3 cells were synchronized as described above and cells were lysed at the 
indicated time points after re-addition of IL-3. Analysis of cells lysed after 8 hours show 
the presence of multiple phosphorylations on both the non-NO-modified form and the 
Figure 8.4. Inhibition of mTOR interferes with phosphorylation of GLO1 during the cell 
cycle.
Phosphorylation of GLO1 with mTOR inhibitors. Ba/F3 cells were synchronized by IL-3 starvation 
over night. The cell cycle was induced by re-addition of IL-3. This time point was designated 0 
hours. Rapamycin was added after 8 hours. Cells were lysed in CEB at indicated time points, and 
after ethanol precipitation resuspended in 2-DE lysis buffer. Protein concentrations were determined 
and 200 µg of the lysates was loaded for separation by 2-dimensional gel electrophoresis (pH 4-
7). Representative western blots of 2-DE gels developed with an anti-GLO1 antibody are shown. 
Differential spots are indicated with arrows on the NO-modified form and with an arrowhead on the 
non-NO-modified form.
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NO-modified form (Figure 8.4, upper panel). After 12 hours, the number of different 
phosphorylations was reduced, with only a phosphorylated NO-modified form, and a 
phosphorylated non-NO-modified form remaining (Figure 8.4, second panel). After 13 
hours, additional phosphorylation can be observed on the non-NO-modified form (Figure 
8.4, third panel, arrowhead), as well as on the NO-modified form (Figure 8.4, third panel, 
arrows). Although the phosphorylations induced at the 13 hour time point, both on the 
NO-modified form and the non-NO-modified form, can be inhibited with rapamycin (Figure 
8.4, fifth panel, arrow and arrowhead respectively), this was not the case after 12 hours. 
In contrast, at 12 hours, addition of rapamycin seemingly enhanced phosphorylation 
Figure 8.5. Inhibition of PI3K/Akt or mTOR inhibits phosphorylation of GLO1 in asynchronously 
growing cells.
A. Phosphorylation of GLO1 with PI3K/Akt inhibitors. Wortmannin was added to exponentially growing 
Ba/F3 cells. Cells were lysed in CEB after 3 hours and after ethanol precipitation resuspended in 2-DE 
lysis buffer. Protein concentrations were determined and 200 µg of the lysates was loaded for separation 
by 2-dimensional gel electrophoresis (pH 4-7). Representative western blots of 2-DE gels developed with 
an anti-GLO1 antibody are shown. B. Phosphorylation of GLO1 with rapamycin. Rapamycin was added 
to exponentially growing Ba/F3 cells. Cells were lysed in CEB after 3 hours and after ethanol precipitation 
resuspended in 2-DE lysis buffer. Protein concentrations were determined and 200 µg of the lysates was 
loaded for separation by 2-dimensional gel electrophoresis (pH 4-7). Representative western blots of 2-DE 
gels developed with an anti-GLO1 antibody are shown. C. In vitro GLO1 activity of exponentially growing 
Ba/F3 cells. Wortmannin or rapamycin was added to exponentially growing Ba/F3 cells. Cells were lysed in 
CEB after 5 hours, lysates were brought to equal concentrations and cell lysates were used to assay GLO1 
activity. Reaction rate of lysates made of exponentially growing cells are set as 100%.
Differential spots are indicated with an arrowhead.
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on the NO-modified forms (Figure 8.4, fourth panel, arrows). On the other hand, the 
phosphorylation on the non-NO-modified form was inhibited (Figure 8.4, fourth panel, 
arrowhead)
Likewise, incubation of asynchronously growing Ba/F3 cells with rapamycin for 3 
hours, strongly changed the phosphorylation of GLO1. Whereas multiple phosphorylations 
could be observed in the absence of rapamycin, these were abolished upon the addition 
of rapamycin (Figure 8.5.B, second and third panel, arrowheads). As well as in the case 
of inhibition with wortmannin, no effects on the activity of GLO1 could be found after 
incubation of Ba/F3 cells in the presence of rapamycin (Figure 8.5.C).
In conclusion, these observations show that phosphorylation of GLO1 in the cell 
cycle occurs in part in a mTOR dependent manner.
DISCUSSION
 GLO1 expression levels and activity have been shown to associate strongly with 
proliferation. This has been reported to be the case in animal cells (10,11,66) as well 
as in plants (22,23,25) and yeast (67). In general it is observed that strongly dividing 
cells and tissues display high GLO1 activity, whereas GLO1 levels and activity drop in 
more quiescent or matured cells and tissues (11,22,68,69). Furthermore, under various 
pathophysiological conditions GLO1 is regulated and higher levels of GLO1 are associated 
with increased proliferation of tumors (14,16-19). The data presented above show that 
during the cell cycle, GLO1 is strongly subjected to phosphorylation. This is in agreement 
with the findings described in chapter 6, where was shown how phosphorylation of 
GLO1 occurred when G1 arrest was induced by GF withdrawal in a GSK-3β dependent 
manner. This took place in several cell lines, suggesting a general mechanism. Of note 
is the apparent absence of the NO-responsive isoform in early G1. It has been described 
that phosphorylation primarily occurs on the NO-responsive isoforms of GLO1, but both 
types of posttranslational modification are independent and neither type of modification is 
required for the other type to occur (48). Phosphorylation could be severely altered by use 
of wortmannin, a PI3K inhibitor, and rapamycin, an inhibitor for mTOR. This suggests the 
involvement of the PI3K/Akt/mTOR signaling cascade. 
 Interestingly, in spite of the strong effects observed with both wortmannin and 
rapamycin, neither one could however completely inhibit GLO1 phosphorylation. Possibly 
this is the consequence of feedback mechanisms or compensatory mechanisms that 
exist in this pathway. Elaborate evidence exists for such mechanisms. Although mTOR 
activation is downstream of PI3K/Akt, mTOR reciprocally phosphorylates Akt, hereby 
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either further activating Akt, when mTOR is part of the mTOR complex 2 with rictor 
(70), or serving as a negative feedback mechanism when mTOR is bound in the raptor 
containing mTOR complex 1 (71,72). Alternatively, there might be several kinases involved 
in phosphorylation of GLO1, depending on the stimulus, or acting in a redundant manner. 
It would also be plausible to hypothesize that inhibition of either Akt or mTOR would result 
in (partial) activation of GSK-3β since both kinases are able to phosphorylate and inhibit 
GSK-3β in vivo (73-77). Moreover, we have shown that GLO1 is a direct substrate for 
CaMKII (chapter 7).
 
 Cycling cells require a dynamic regulation of glucose metabolism. The presence of 
glucose is a requisite for cells to proliferate and it has been observed that cells upregulate 
glucose uptake and glucose metabolism during G1 and S phase and downregulate 
glucose uptake during G2/M phase (31,32,78). GFs play an essential role by promoting 
cell metabolism and determining the rate of cell division. The PI3K/Akt pathway is critically 
involved in GF signaling in hematopoietic cells and directly affects the glucose metabolism 
(34,36,39,79) as well as the cell cycle (42,80-82). It would therefore be reasonable to 
hypothesize that GFs would attach a dynamic regulation of the GLO system to the cell 
cycle determined regulation of glycolysis, since a rise in the rate of glycolysis would be 
expected to automatically implicate higher intracellular levels of the cytotoxic MG. Our data 
show, however, that different phases in the cell cycle did not display different levels of in 
vitro GLO1 activity (Figure 8.2.A), in contrast with the described rise in G2/M, which has 
been described in carrot cell suspension cultures (52). Also at the G1-S transition, no higher 
levels of GLO1 were observed in vitro (Figure 8.2.B), in spite of the fact that from literature 
we would expect a rise in glucose uptake and glycolysis (32,83-86). On the other hand, it 
has been shown that higher GLO1 activity, even when adequate concentrations of reduced 
glutathione are present, not necessarily suffices to keep intracellular concentrations of 
MG low (87), which could make a rise in GLO1 activity redundant. Furthermore, addition 
of rapamycin or wortmannin did not have an effect on GLO1 activity in vitro, despite the 
drastic changes that were induced on phosphorylation. These data should however be 
interpreted cautiously since they do not exclude the possibility that in the cells GLO1 
activity might differ locally, hereby creating microenvironments with different levels of MG. 
Alternatively GLO1 isoforms have been described that are not involved in detoxification of 
MG (88), and possibly these isoforms are phosphorylated during the cell cycle.
 In summary, our data shows that GLO1 is subject to several phosphorylations 
during the cell cycle, but this does not seem to influence the activity of GLO1. These 
phosphorylations are in part mediated by the PI3K/Akt/mTOR signaling cascade. 
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MATERIALS AND METHODS
Cell Lines and Cultures 
 The IL-3 dependent pro-B cell line Ba/F3 (89) was purchased from DSMZ. Ba/
F3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with glutamax 
(Invitrogen) supplemented with heat-inactivated FBS (10% v/v) (Cambrex), penicillin (100 
units/ml) and streptomycin (0.1 mg/ml) and 5% conditioned medium from WEHI-3B cells as 
a source of mouse IL-3. Ba/F3 cells were cultured at 37°C in a humidified incubator under 
an 5% CO2 atmosphere. 
Cell stimulations
Ba/F3 cells were synchronized by washing exponentially growing cells 3 times 
in culture medium without conditioned WEHI-3B medium and resuspension in culture 
medium without conditioned WEHI-3B medium for 8 hours or overnight. At the end of the 
synchronisation conditioned WEHI-3B medium (5% v/v) was re-added. This time point 
was designated 0 hours. Alternatively was added for 8 hours or overnight. At the end of 
the synchronisation nocodazole was removed by washing cells 2 times in fresh culture 
medium. This time point was designated 0 hours.
Chemicals and inhibitors used are nocodazole (Sigma aaldrich), wortmannin and 
rapamycin (Calbiochem). Duration and concentrations used as described.
DNA distribution analysis
 Cells were stained with propidium iodide (PI, Sigma) containing staining solution 
(90) and analyzed by a FACSCalibur flow cytometer (488Ex/590Em). Cell Quest software 
was used to analyze cell cycle distribution (FACS Calibur, Becton Dickinson) (90,91). Ten 
thousand cells were routinely analyzed.
Electrophoresis and immunoblotting
The cells were washed 3 times with ice-cold PBS buffer and lysed with cytosol 
extraction buffer (10 mM Tris-HCL pH7.4, 50 mM EDTA pH8.0, 25 mM NaCl, 0,7% 
TritonX-100, 100 mM PMSF, 1 tablet Complete Protease Inhibitor Cocktail (Roche)/50 ml 
cytosol extraction buffer). Cell lysates were cleared by centrifugation (14,000 x g). Protein 
concentrations were determined using Bradford method. Proteins were separated by 
SDS-PAGE and transferred onto a PVDF membrane (Hybond-P, Amersham Pharmacia 
Biotech). The blots were incubated with the desired antibodies followed by ECL-based 
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detection (Amersham Pharmacia Biotech).
2-Dimensional Gel Electrophoresis 
Isoelectric focusing was carried out on 18 cm IPG strips, pH 4-7 (GE Healthcare) 
according to the manufacturer’s instructions. For the second dimension, proteins were 
separated by SDS-polyacrylamide gel electrophoresis (PAGE, 12%).
Determination of GLO1 activity
GLO1 activity was determined as described earlier (47), using the spectrophotometric 
method developed by Oray and Norton (92). Equal concentrations of cell lysates were 
used.
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Supplementary figure 1. Prediction of phosphorylation sites in glyoxalase I.
A. Alignment of the amino acid sequence of human and mouse GLO1 as found in UniProtKB/Swiss-Prot. 
Potential phosphorylation sites as predicted by Netphos software are indicated in bold. The potential 
phosphorylation sites that were described for human GLO1 in (1) are indicated within boxes. Predicted 
phosphorylation sites for CaMKII (*), GSK-3 (+), PKA () and Akt () were determined using Motifscan 
software (low stringency). 
B and C. Scores of predicted phosphorylation sites as obtained using Netphos software for human (A) and 
mouse (B) GLO1.
 1.  Ranganathan, S., E. S. Walsh, A. K. Godwin, and K. D. Tew. 1993. Cloning and Characterization of Human 
Colon Glyoxalase-I. Journal of Biological Chemistry 268:5661-5667.
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Chapter 9: The Receptor for Advanced Glycation Endproducts 
(RAGE) is regulated at several levels during the cell 
cycle
A novel proteolytically generated form of RAGE
INTRODUCTION
 
 The receptor for advanced glycation endproducts (RAGE) was first isolated 
as a receptor for advanced glycation endproducts (AGEs), which are adducts formed 
by glycation and subsequent oxidation of proteins (1,2). RAGE is a member of the 
immunoglobulin superfamily of receptors and has been suggested to be involved in 
embryonic development, since it has been reported to be expressed during development, 
repressed in adulthood and re-expressed in several pathologies (3). Although the original 
ligand to be identified for RAGE were AGEs, a remarkable feature of RAGE is its ability 
to be activated by different other specific ligands such as amphoterin (often referred to 
as high mobility group box I (HMGB1) DNA-binding protein) (4), several members of 
the S100 Ca2+-binding protein family (5,6), and β-sheet fibrils and amyloid-β-peptide 
(7,8). Multifarious signaling pathways are induced upon RAGE activation, including the 
reactive oxygen species (ROS)-dependent activation of mitogen-activated protein kinases 
(MAPKs) (9-12), other MAPK pathways, such as the p38 pathway and the stress-activated 
protein/c-Jun N-terminal kinase (SAPK/JNK) (11,13,14), Janus kinase/signal transducer 
and activator of transcription (JAK/STAT) pathways (15,16), the small GTPases cdc42 and 
rac (17) and the phosphoinositol-3-kinase (PI3K) pathway (18,19). To date, the full range 
of different signaling pathways initiated by RAGE activation has not been elucidated. Also 
the intracellular factors that bind to the cytoplasmic tail of RAGE remain to be determined. 
The outcome of RAGE signaling is highly dependent on the cell type, the available ligands 
and their concentrations, and the different levels and isoforms of RAGE, all of this adding 
further to the complexity of RAGE signaling.
 RAGE activation has been implicated in cell cycle related signaling. Although 
proliferation and differentiation are sequential and mutually exclusive events, RAGE has 
been involved in both, depending on the ligand and cell type. RAGE activation is often 
considered to promote tumor growth and metastasis, and the level of RAGE expression 
is regarded as a measure for metastatic potential of tumor cells (13,20-29). In neuronal 
cells it was reported that both AGEs as well as S100B could elicit a mitogenic response 
through RAGE, hereby upregulating cyclin D1 expression and urging cells into S phase in a 
p42/44 MAPK dependent manner (30,31). Also in other cell types, such as fibroblasts (29), 
osteoblasts (9), smooth muscle cells (26) and mesangial cells (23), activation of RAGE 
induced MAPK activation and subsequent cell growth.
Part II: Experimental Data and Results
118
Chapter 9: Regulation of RAGE 
119
 However, in spite of the elaborate evidence for a role of RAGE in proliferation, this 
has been contradicted by several reports. In melanoma and neuroblastoma cells RAGE 
activation by amphoterin led to inhibition of metastasis in vivo (32). Further it has been 
reported that overexpression of full-length RAGE (FLRAGE) did not promote metastasis of 
lung cancer cells in vivo, but instead showed a diminished proliferation in vitro (33,34). It 
was also shown that higher tumor stages and several other metastatic tissues displayed a 
downregulation of RAGE (35). The same was observed after overexpression of RAGE in 
rhabdomyosarcoma cells, where binding of amphoterin to RAGE stimulated differentiation 
in a cdc42 and p38 dependent manner (36). In the development of diabetic nephropathy 
it was observed that AGE interaction with RAGE activated STAT5–mediated upregulation 
of p21waf and consequent growth arrest (37). Furthermore, both amphoterin and AGE-BSA 
are able to stimulate maturation of dendritic cells (38,39).
 
 The ambiguous function of RAGE in the regulation of cell cycle may find its basis 
partly in the presence of different isoforms of RAGE. RAGE signaling is not mediated 
by the action of a single type of RAGE receptor, but relies on the interplay of different 
factors, such as the level of RAGE expression, the presence and relative concentrations of 
different ligands, the large number of different isoforms and their possible splice variants, 
and possible posttranslational modifications of RAGE (reviewed in (40,41)). Furthermore, 
the outcome of RAGE signaling is, above all, highly dependent on the cell type. We 
commenced the study for the involvement of RAGE in the regulation of the cell cycle by 
studying the differential expression of RAGE isoforms. A twofold approach was used. 
Cells were synchronized and the different phases and phase transitions were studied. 
Alternatively, G1 arrest was induced in Ba/F3 cells or Hek293 cells by IL-3 depletion or 
serum starvation respectively.
RESULTS
Ba/F3 cells exhibit different isoforms of RAGE
 First, we studied the expression of the different isoforms of RAGE. Several different 
isoforms have already been described, the major isoforms being FLRAGE, the soluble 
RAGE (SRAGE) which lacks the transmembrane domain and the cytoplasmic domain and 
the dominant negative RAGE (DNRAGE) which lacks the cytoplasmic domain (reviewed in 
(40)). Several other isoforms have also been described, but their expression is cell type 
dependent (41,42). The antibody used was an antibody raised against the C-terminus of 
RAGE (C-t-Ab; Abcam). Soluble isoforms of RAGE would therefore be missed in our study 
since they have alternative C-termini (43,44). However, the specificity of this antibody was 
confirmed by the specific recognition of RAGE on Western blots from wild type mouse lung 
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extracts, whereas RAGE was not detected in lung extracts from RAGE-/- mice (Salliau et 
al., submitted). 
 In total lysates from asynchronously growing Ba/F3 cells several isoforms are 
present (Figure 9.1). The band migrating at 50 kDa is FLRAGE (44,45). FLRAGE can be 
severely glycosylated, which is known to result in bands of higher molecular weight, such 
as the 52 kDa, the 55 kDa and the two bands near the 75 kDa marker (44,46).  Further 
we observed the presence of several high molecular weight bands. These high molecular 
weight bands are hypothesized to result from oligomerization or complexes with other 
proteins (43,47). Also a band of 42 kDa is present in Ba/F3 cells. This band has been 
described as a N-terminal truncated form of RAGE (44). Further bands of 37 kDa and 27 
kDa can be observed, which are hypothesized to be processed and truncated forms of 
RAGE ((43); Salliau et al., submitted).  Furthermore, a band of approximately 17 kDa can 
be seen. This is a novel proteolytic processed isoform and will be discussed below. 
 It should be noted that RAGE not only appears on the plasmamembrane. Some 
isoforms, among which FLRAGE, also appear in the cytosol and the nucleus (Salliau et al., 
submitted).
RAGE expression is altered during the cell cycle
 We then analysed whether different phases are associated with differences in the 
expressed RAGE isoforms. G1 arrest was induced by IL-3 depletion and G2/M arrest by 
addition of nocodazole. The analysis of DNA distribution on FACS confirmed the respective 
phases arrests (Figure 9.2.B). Lysates of cells arrested in either G1 or G2/M were compared 
with lysates of asynchronously growing cells. Nocodazole-treated cells showed an 
upregulation of the expression of a band with an apparent molecular weight of 42 kDa 
(Figure 9.2.A lane 2, indicated with an arrowhead). This band corresponds to the band that 
has been described to be a N-terminal truncated isoform, which lacks the N-terminal V-
Figure 9.1. RAGE isoforms in Ba/F3 cells.
Isoforms of RAGE in Ba/F3 cells. Exponentially growing Ba/F3 cells were lysed in CEB. 40 µg of protein was 
separated by SDS-PAGE and transferred onto PVDF using electrotransfer. Expression of different isoforms 
of RAGE was analysed using the C-terminus-directed anti-RAGE antibody (C-t-Ab; Abcam).
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type immunoglobulin-like domain (43,44). This upregulation was not observed in the cells 
that were arrested in the G1 phase (Figure 9.2.A, lane 3). Also the high molecular weight 
isoforms displayed different levels of expression when the G1 and G2/M arrested cells were 
compared with asynchronously growing cells. These high molecular weight bands were 
specific for the cytosolic fraction and could not be observed in nuclear fractions (data not 
shown). In the lysate of the asynchronously growing culture, two intense protein bands are 
observed between with molecular weights of approximately 80 kDa and 100 kDa, with in 
between them a less intense band of approximately 90 kDa (Figure 9.2.A, indicated with 
arrows). The 80 kDa band was downregulated in the G2/M-arrested cells, whereas in the 
G1–arrested cells the inverse was observed, and the 90 kDa band and the 100 kDa band 
were expressed substantially less. 
 In this context, we additionally studied whether the change of the expressed 
Figure 9.2. Cell cycle phase specific RAGE expression.
A. Analysis of RAGE in different phases. G1 arrest was induced by IL-3 starvation of Ba/F3 cells and G2/M 
arrest was induced by addition of nocodazole. Cells were lysed in CEB, equal protein concentrations were 
separated by SDS-PAGE and transferred onto PVDF using electrotransfer. Expression of different isoforms 
of RAGE was analysed using the C-t-Ab. B.  Analysis of the cell cycle. Induction of the different phase arrests 
were monitored by analysis of the DNA content by flow cytometry.
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Figure 9.3. Differential expression of RAGE at phase transitions. 
A. Isoforms of RAGE at G1-S transition. B. Isoforms of RAGE at S-G2/M transition. Ba/F3 cells were 
synchronized by IL-3 starvation over night. Cell cycle was induced by readdition of IL-3. This time point was 
designated 0 hours. Cells were lysed in CEB at indicated time points and equal protein concentrations were 
separated by SDS-PAGE and transferred onto PVDF using electrotransfer. Expression of different isoforms 
of RAGE was analysed using the C-t-Ab. Blots were subsequently stripped and reprobed with an anti-cyclin 
E antibody (Abcam) (A) or an anti-cyclin A antibody (Santa Cruz) (B). Protein band intensities were measured 
using Genetools software (Westburg) and corrected for equal concentrations.The relative intensities of the 
100 kDa isoform and the 90 kDa isoform are represented by black and white bars respectively in (A) and the 
90 kDa isoform and the 80 kDa isoform are represented by black and white bars respectively in (B). 
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isoforms coincided with the transition of different phases. Hence, cells were synchronized 
by IL-3 withdrawal and lysates were made after the appropriate time intervals after re-
addition of IL-3 to release cell cycle arrest (indicated by hours after re-addition of IL-3). The 
transgression of the cells through the different phases of the cell cycle was observed by 
analysis of the DNA distribution on FACS and the transition of G1 to S was confirmed by 
the rise of the level of cyclin E (Figure 9.3.A, lower panel indicated with an arrow), a marker 
for late G1 and S phase. Immunoblotting of the obtained lysates endorsed the observation 
that differential expression of RAGE isoforms coincides with specified phases (Figure 9.3). 
When the progression through G1 phase towards S phase was studied (Figure 9.3.A), 
we observed a strong decline of the 80 kDa isoform of RAGE throughout G1, reaching its 
lowest level at 7 hours, where it only retains 15 % of its initial intensity (Figure 9.3.A, upper 
panel indicated with an arrow and chart, white bars). 9 hours after the re-addition of IL-3 to 
remove the cell cycle block, this 80 kDa isoform is then upregulated to approximately 40 
% of its initial level. This time corresponds to the beginning of the S phase. Concomitantly 
with the downregulation of 80 kDa band, the 100 kDa isoform of RAGE (Figure 9.3.A) is 
upregulated throughout G1, reaching its maximum level at the end of G1, when expression 
levels of the 80 kDa isoform is lowest, and its expression level slightly decreases after 
the onset of S, 9 hours after the release of the cell cycle block (Figure 9.3.A, upper panel 
indicated with an arrowhead and chart, black bars). 
 Also at the transition of the S to the G2 phase was studied. While 100 kDa RAGE 
isoform remained constant throughout this study, a rapid decline was observed in the 
Figure 9.4. Cell surface staining for RAGE expression.
Ba/F3 cells were synchronized by IL-3 starvation over night. Cell cycle was induced by readdition of IL-3. 
This time point was designated 0 hours. Staining occurred at indicated timepoints using a N-terminus-
directed anti-RAGE antibody (Santa Cruz). Gray filled histograms represent isotype control and black 
histograms represent RAGE expression.
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90 kDa band, reaching its lowest levels of approximately 20 % of the initial intensity 16 
or 17 hours after the release of the cell cycle arrest. This time point coincides with the 
transgression from the S phase to the G2 phase (Figure 9.3.B, upper panel indicated with 
an arrowhead and chart, black bars). The 80 kDa RAGE isoform also decreased during S 
phase, and reached minimum levels after 19 hours in late G2 phase (Figure 9.3.B, upper 
panel indicated with an arrow and chart, white bars). S to G2 transition was marked by the 
decrease of the level of cyclin A, a marker for S phase (Figure 9.3.B, lower panel indicated 
with an arrow).
 Subsequently, we measured the membrane expression levels of RAGE on FACS. 
In spite of the strong alterations in high molecular weight isoforms of RAGE during the cell 
cycle, we could not correlate these observations to differences in the membrane expression 
levels (Figure 9.4). 
 In summary, we show that expression of RAGE is strongly regulated throughout the 
cell cycle. This regulation occurs mainly intracellularly and is not related to different levels 
of localization of RAGE on the plasmamembrane.
RAGE is processed into a 17 kDa isoform during G1 arrest
 As shown in Figure 9.1 we detected a novel isoform of RAGE of approximately 17 
kDa in asynchronously growing Ba/F3 cells. This isoform, which will be designated 17 kDa 
RAGE, has not been reported to date. Cellular fractionation revealed this isoform was 
present predominantly in the nuclear and membrane fractions, and could be distinguished 
much less in cytosolic fractions (data not shown). 
 To examine whether this novel isoform could be connected to a particular phase, 
we compared lysates of asynchronously growing Ba/F3 cells with lysates from Ba/F3 
cells that were arrested in G1 by IL-3 depletion and nocodazole-induced G2/M arrested 
Ba/F3 cells. As shown in Figure 9.5.A, a strong induction of 17 kDa RAGE was observed 
specifically in the G1 arrested cells (Figure 9.5.A, arrow). This induction was specific, since 
no upregulation of FLRAGE was observed (Figure 9.5.A, arrowhead). The induction of G2/
M arrest and G1 arrest by nocodazole and IL-3 depletion respectively were confirmed by 
analysis of the DNA-distribution on FACS (Figure 9.5.B). Subsequently Ba/F3 cells were 
synchronized by IL-3 depletion and re-addition of IL-3 and RAGE expression was studied 
throughout the cell cycle. The 17 kDa RAGE isoform could also be detected in the S phase 
(Figure 9.5.C), where it seemed to be up- and downregulated in an alternating fashion 
(Figure 9.5.C, arrow), in contrast to FLRAGE, which appears to remain constant (Figure 
9.5.C, arrowhead). 
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 Together we show the existence of a novel isoform of RAGE, which is strongly 
induced during G1 arrest, although it also occurs during the cell cycle.
Kinetics of 17 kDa RAGE generation
 Since prolonged absence of IL-3 also leads to the induction of apoptosis in Ba/F3 
Figure 9.5. Novel 17 kDa isoform of RAGE.
A. Analysis of 17 kDa RAGE in different phases. G1 arrest was induced by IL-3 starvation of Ba/F3 cells and 
G2/M arrest was induced by addition of nocodazole. Cells were lysed in CEB, equal protein concentrations 
were separated by SDS-PAGE and transferred onto PVDF using electrotransfer. Expression of different 
isoforms of RAGE was analysed using the C-t-Ab. B Analysis of the cell cycle. Induction of the different 
phase arrests were monitored by analysis of the DNA content by flow cytometry. C. 17 kDa RAGE at G1-S 
transition. Ba/F3 cells were synchronized by IL-3 starvation over night. Cell cycle was induced by re-addition 
of IL-3. This time point was designated 0 hours. Cells were lysed in CEB at indicated time points equal protein 
concentrations were separated by SDS-PAGE and transferred onto PVDF using electrotransfer. Expression 
of different isoforms of RAGE was analysed using the C-t-Ab.
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cells we next studied the kinetics of 17 kDa induction in Ba/F3 cells. In the experiment 
shown, induction of 17 kDa RAGE was detected after 6 hours of IL-3 depletion (Figure 9.6), 
well before the onset of apoptosis and further increased at later time points. 
 We were also interested in whether addition of exogenous methylglyoxal (MG) could 
influence the formation of 17 kDa RAGE. MG is a very potent glycating agent of proteins and 
the most important precursor of advanced glycation endproducts (AGEs) (48,49). RAGE 
is known to be upregulated in the presence of its ligands, providing a positive feedback 
loop when activated (50,51). Moreover, it has been shown that exogenous MG is strongly 
synergistic with the depletion of IL-3 in the induction of apoptosis in Ba/F3 cells (Audiffret et 
al., submitted, see also chapter 6). IL-3 depletion-induced generation of 17 kDa RAGE was 
already observed after 3 hours upon addition of exogenous MG (Figure 9.6). Furthermore, 
the level of 17 kDa RAGE, induced by IL-3 depletion, was substantially higher than in the 
absence of exogenous MG. 
17 kDa RAGE is also generated in Hek293 cells
 To corroborate our findings in Ba/F3 cells we tested if 17 kDa RAGE could also 
be detected in other cell lines. Hek293 cells were therefore transiently transfected with a 
vector expressing FLRAGE and cells were depleted of serum 24 hours after transfection. 
Cells were lysed 24 hours after depletion and analyzed by immunoblotting with C-t-Ab 
(Figure 9.7.A). In control cells and mock transfected cells, the 17 kDa RAGE could not be 
detected. However, when cells were transfected with FLRAGE and cultured in the absence 
of serum, the formation of 17 kDa RAGE was induced. This shows that the 17 kDa RAGE 
is not restricted to a specific cell line or species (mouse and human), hereby suggesting 
induction of 17 kDa RAGE is a general mechanism. In addition, 17 kDa RAGE was also 
observed in the mouse β-cell line MIN6 (Toepoel et al., unpublished results). 
 Several mechanisms can be responsible for the formation of 17 kDa RAGE, the 
two most plausible are alternative splicing and proteolytic cleavage. To examine these 
Figure 9.6. 17kD RAGE induction by exogenous MG.
G1 arrest was induced by depletion of IL-3 and exogenous MG was added. Cells were lysed in CEB after 
indicated time intervals, equal protein concentrations were separated by SDS-PAGE and transferred onto 
PVDF using electrotransfer. Expression of different isoforms of RAGE was analysed using the C-t-Ab.
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mechanisms, Hek293 cells were transiently transfected with vectors containing the cDNA 
encoding C-terminal flagged RAGE and N-terminal flagged RAGE (designated RAGE-
C-flag and N-flag-RAGE respectively). As expected, analysis of immunoblots with an 
antibody directed against the flag-tag showed high levels of overexpression of RAGE with 
either construct. However, the generation of 17 kDa RAGE could be observed using an 
antibody raised against the flag-tag, only when this tag was attached at the C-terminus of 
RAGE, hereby validating the observations made with the C-terminus directed anti-RAGE 
antibody (Figure 9.7.B). Most isoforms described to date have been reported to result from 
alternative splicing and posses different C-termini (reviewed in (40,41)). However, since 17 
kDa RAGE can also be generated by overexpression of RAGE using a cDNA, alternative 
splicing can be excluded. 
 In the lysates of the cells transfected with N-flag-RAGE an additional band could be 
observed with a molecular mass of approximately 45 kDa (Figure 9.7.B, arrowhead). This 
band could very well be the remainder of the cleaved RAGE. The molecular weight differs 
from the band seen near the 75 kDa marker, which probably represents the glyosylated full 
length flag-tagged RAGE, and the difference in molecular weight could be explained by the 
removal of the 17 kDa RAGE part. This band was absent in the lysates of cells transfected 
with the RAGE-C-flag, endorsing that this isoform had an alternative C-terminus, but an 
intact N-terminus. Several reports indicate the involvement of protein cleavage in the 
formation of a soluble form of RAGE in mice (43,52). Moreover, recently it has been 
reported that limited proteolysis of RAGE with trypsin also gives rise to low molecular 
weight bands with comparable migratory properties (47), hereby further emphasizing the 
hypothesized proteolytic cleavage of RAGE. It should be noted however that 17 kDa was 
present even when serum was not depleted.
Inhibition of caspases partially inhibits the generation of 17 kDa RAGE
 Our data excludes alternative splicing as a mechanism to generate 17 kDa RAGE 
and suggest the involvement of proteolytic cleavage. Proteolytic cleavage was subsequently 
further explored by using several specific inhibitors. Initial experiments with different 
protease inhibitors showed no effects (data not shown). Since IL-3 starvation of Ba/F3 
cells also leads to apoptosis, we sought to determine if the inhibition of caspase activation 
could inhibit formation of 17 kDa RAGE. When Ba/F3 cells were starved of IL-3, 17 kDa 
RAGE formation was induced, as observed by analysis of lysates using immunoblotting 
with C-t-Ab. In the presence of the pan-caspase inhibitor Z-VAD-FMK however generation 
of 17 kDa RAGE was partially inhibited (Figure 9.8.A, arrow). Other isoforms, such as the 
50 kDa from were unaffected (Figure 9.8.A, arrowhead). Subsequently Hek293 cells were 
transiently transfected with pCAGGS-RAGE-C-flag and depleted of serum in the presence 
of Z-VAD-FMK. As observed by immunoblotting with an antibody against flag, inhibition of 
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caspase activation led to a decrease in 17 kDa RAGE (Figure 9.8.B). Formation of 17 kDa 
RAGE was inhibited by Z-VAD-FMK to the same extent in Hek293 cells as in Ba/F3 cells. 
 Interestingly, in the modelsystem with RAGE overexpression in Hek293, a strong 
induction of 17 kDa was observed, even in the presence of serum (Figure 9.7.B and 9.8.B). 
Figure 9.7. Generation of17 kD RAGE in Hek293 cells.
A. Presence of 17 kDa RAGE in Hek293 cells. Hek293 cells were transfected with expression vectors 
containing full length RAGE. After 24 hours, transfected cells were serum-starved over night. Lysates 
were made in CEB and equal protein concentrations were separated by SDS-PAGE and transferred onto 
PVDF using electrotransfer. Expression of different isoforms of RAGE was analysed using the C-t-Ab. 
B. Formation of 17 kDa RAGE in Hek293 cells. Hek293 cells were transfected with expression vectors 
containing either N-flag-RAGE or RAGE-C-flag. After 24 hours, transfected cells were serum-starved for 1 
or 2 days. Lysates were made in CEB and equal protein concentrations were separated by SDS-PAGE and 
transferred onto PVDF using electrotransfer. Expression of different isoforms of RAGE was analysed using 
an anti-flag antibody (Sigma Aldrich).
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A possible hypothesis would be it is induced by the G1 arrest caused by contact inhibition 
(53-56). In the presence of serum, however, addition of Z-VAD-FMK led to a strong rise in 
the level of 17 kDa RAGE.
Analysis of posttranslational modification of RAGE during the cell cycle using 2-
dimensional gel electrophoresis
 In order to further examine the possible involvement of RAGE in the cell cycle 
we also analyzed whether posttranslational modification of RAGE occurs during the cell 
cycle, using 2-dimensional gel electrophoresis (2-DE). The cell cycle of Ba/F3 cultures 
was synchronised in the G1 phase by IL-3 depletion over night and subsequently released 
from this block by re-addition of IL-3. Cells were lysed at different time points after the re-
addition of IL-3, when cells were in different phases of the cell cycle. 
Immunoblots are shown in Figure 9.9.A which were detected with C-t-Ab. Although 
the most acidic isoform remains constant, the displayed isoforms strongly alternate. The 
upper panel shows lysates of a Ba/F3 culture in G1. Three isoforms can be distinguished at 
this time, the two most acidic however are not well separated and appear almost fused. In 
the S phase, the middle spot disappeared, and seems to have merged with the most acidic 
spot. In the G2/M phase the pattern of the two most acidic isoforms strongly resembles the 
pattern in G1, but the basic isoform had vanished. Early in the G1 phase of the following 
cycle, the most basic isoform reappears and in late G1 two new spots arise, more basic 
than the basic spot observed so far. The newly formed basic spots then seem to shift again 
towards the more acidic side during the S phase.
 To date the only posttranslational modification described for RAGE is glycosylation 
(43-45). Differences in glycosylation have however been shown to result in differences 
in molecular weight, which are not observed here. Unpublished data from Salliau et al. 
suggest phosphorylation might play a part in the alternating pattern observed. The short 
cytoplasmic domain of RAGE contains 2 predicted sites for phosphorylation, and when 
RAGE was purified from metabolically labeled L929 cells, specific spots were observed 
on autoradiographs from 2D gels (Salliau et al., unpublished data). Since these patterns 
observed on 2-dimensional electrophoresis strongly resemble the patterns observed for 
GLO1 and arise analogous with the modifications of GLO1 (see chapter 6 and data not 
shown), it is conceivable that phosphorylation indeed is responsible for at least part of the 
modifications observed.
 To further substantiate the cell cycle-dependent modification of RAGE, we then 
investigated if the induction of G1 arrest by the depletion of IL-3 also induced alterations in 
the pattern of displayed isoforms of RAGE (Figure 9.9.B). We depleted Ba/F3 cells of IL-3 
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and lysates were made after the indicated time intervals. Asynchronously growing Ba/F3 
cells displayed four isoforms, the pattern showed strong similarities with the pattern seen 
in late G1 (Figure 9.9.A), but a fourth spot was also detected, situated between the most 
acidic isoform and the duplet of more basic isoforms. After 1 and 3 hours the second most 
acidic isoform vanishes and the most basic spot shits towards the more basic side. After 
7 hours of IL-3 starvation only three isoforms remain and the observed pattern strongly 
resembles the pattern observed in late G1.
DISCUSSION
 Activation of RAGE is not completely understood and knowledge is only fragmented. 
RAGE expression is high during development, repressed in mature tissues, and upregulated 
again in the course of several pathologies such as in different cancers, so RAGE signaling 
has often been involved in the regulation of cell cycle (3). The involvement of RAGE in 
proliferation however seems rather dualistic, since RAGE activation has been shown to 
be involved in proliferation (9,23,26,30,31) as well as in growth arrest and differentiation 
(32,36-38,57,58), two processes that are consecutive and mutually exclusive.
 Three major isoforms of RAGE have been described (reviewed in (40)). However, 
additional splice variants and isoforms keep on being discovered, sometimes with a high 
Fig. 9.8. Inhibition of the generation of 17 kDa RAGE.
A. 17kDa RAGE generation in Ba/F3 cells. Ba/F3 cells were IL-3-depleted and Z-VAD-FMK (20 µM) was 
added. After 24 hours, cells were lysed in CEB and equal protein concentrations were separated by SDS-
PAGE and transferred onto PVDF using electrotransfer. Expression of different isoforms of RAGE was 
analysed using the C-terminus-directed anti-RAGE antibody. B. Generation of 17 kDa in Hek293 cells. 
Hek293 cells were transfected with expression vectors containing RAGE-C-flag. After 24 hours, transfected 
cells were serum-starved over night and Z-VAD-FMK (20 µM) was added. Lysates were made in CEB and 
equal protein concentrations were separated by SDS-PAGE and transferred onto PVDF using electrotransfer. 
Expression of different isoforms of RAGE was analysed using an anti-flag antibody.
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specificity for certain tissues (41,42). Hence, the outcome of RAGE signaling is most likely 
highly tissue-specific. Moreover, it is clear that effects mediated by RAGE are not so much 
the result of one specific isoform of RAGE, but of a concerted interplay of the different 
isoforms and the relative availability of different ligands. This prompted us to study which 
different isoforms are present in Ba/F3 cells and whether these were regulated in a cell 
cycle dependent manner. Although we did not detect a difference in total RAGE expression 
on the membrane, RAGE expression was indeed strongly modulated throughout the cell 
cycle. We were able to correlate different forms of RAGE to different phases in the cell 
cycle and we observed modulation of these  isoforms at phase transitions.
 However, given the high molecular weight of the isoforms described, the observed 
effects can be disputable. The high molecular weight isoforms of RAGE observed are 
hypothesized to be oligomers or complexes containing RAGE. Such complexation and 
oligomerization has been described for RAGE (43,47,59). Moreover, the specificity of the 
antibodies we used was demonstrated earlier (Salliau et al., submitted). Our hypothesis is 
further emphasized by the observation of high molecular weight bands when flag-tagged 
RAGE was overexpressed in Hek293 cells. Immunoblotting with an antibody raised against 
Figure 9.9. RAGE is modified during 
the cell cycle and IL-3 withdrawal-
induced G1 arrest.
A.  RAGE is posttranslationally modified 
during the cell cycle. Ba/F3 cells were 
synchronized by IL-3 starvation over 
night. Cell cycle was induced by 
readdition of IL-3. Samples were taken 
in several phases of the cell cycle. 
Cells were lysed in CEB and after 
ethanol precipitation resuspended in 2-
DE lysis buffer. Protein concentrations 
were determined and 200 µg of the 
lysates was loaded for separation by 
2-dimensional gel electrophoresis (pH 
4-7). Representative western blots of 
2-DE gels developed with C-t-Ab. B. 
RAGE is posttranslationally modified 
during IL-3 withdrawal-induced G1 
arrest. Ba/F3 cells were depleted of 
IL-3, cells were lysed in CEB at the 
indicated time points and after ethanol 
precipitation resuspended in 2-DE 
lysis buffer. Protein concentrations 
were determined and 200 µg of the 
lysates was loaded for separation by 
2-dimensional gel electrophoresis (pH 
4-7). Representative western blots of 
2-DE gels developed with C-t-Ab.
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the flag-tag also showed high molecular weight bands (data not shown).
 
 We also demonstrated the presence of a novel low molecular weight isoform of 
RAGE. This isoform is strongly induced during G1 arrest, but was present at several time 
points in the S phase as well. This isoform was not restricted to one specific cell type, 
since it could be observed in three different cell lines and two different species, mouse and 
human. This low molecular weight from of RAGE was most likely a product of proteolytic 
processing of FLRAGE since it also was formed upon overexpression from a C-terminally 
tagged RAGE, expressed from a cDNA, hereby excluding splicing. The precise mechanism 
could not be clarified yet. However, addition of MG, a cytostatic and cytotoxic compound 
which exerts part of its activity in a RAGE-dependent manner (60), strongly enhanced 
formation of this isoform.  
 Formation of 17 kDa RAGE upon IL-3 or serum starvation could partially be inhibited 
by inhibition of caspases. However, overexpression of full length RAGE could also strongly 
induce formation of 17 kDa RAGE, even in the presence of serum. This formation could not 
be inhibited by caspase inhibition, but addition of Z-VAD-FMK even seemed to enhance 
its formation, hereby seemingly contradicting the observations made in the depletion 
model system. Possibly different or redundant mechanism underlie these observations. 
RAGE could be processed in order to attenuate the strong signaling caused by the high 
levels of RAGE expression. Alternatively, the presence of the C-terminal flag-tag could 
interfere with the function of RAGE, leading to the breakdown of the receptor. The strong 
formation of 17 kDa RAGE in Hek293 cells in the presence of serum was not joined by an 
increase in apoptosis, suggesting that the presence of 17 kDa RAGE per se did not induce 
apoptosis.
 The hypothesis that 17 kDa RAGE is formed by proteolysis is in line with earlier 
observations (43,52). Proteolytic cleavage of RAGE might be an important event in the 
regulation of RAGE signaling and it is conceivable that proteolytic processing of RAGE 
provides a negative regulation or a negative feedback loop in RAGE signaling. Either to 
inhibit prosurvival signaling or signaling towards proliferation, when IL-3 or serum is absent, 
or to downregulate RAGE signaling to prevent overactivation. 
 When high resolution 2-DE was used to study post translational modification of 
RAGE, our data further substantiate that RAGE is strongly susceptible to regulation during 
the progression of the cell cycle and when growth arrest is induced by IL-3 depletion. To 
date the only described posttranslational modification of RAGE is glycosylation (43-46). 
The different spots we observed could be differences in the level of glycosylation, since 
this would yield a different pI and deglycosylation would be able to account for the shifts 
observed. Glycosylation would however also alter the molecular weight of the isoforms, 
and deglycosylation would therefore not only induce a shift towards the basic side, but 
most likely also result in a faster migration in the second dimension. However, while we 
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were able to observe differences in pI, concomitant reductions in molecular weight could 
not be detected.
 We observed that the shifts in pI strongly coincided with the modifications observed 
in GLO1 (see chapter 6 and data not shown). Furthermore, results from our lab showed 
that when L929 cells were metabolically labelled and stimulated with tumor necrosis 
factor (TNF), RAGE could be phosphorylated (Salliau, unpublished results). These 
observations suggest that the modifications shown are possibly phosphorylation and 
dephosphorylation.
 In summary, the data shown here indicate a strong regulation of RAGE during the cell 
cycle. This regulation appears to take place at several levels. At a first level, we observed 
a strong correlation of certain isoforms with different cell cycle phases. This different 
expression could not be related to the expression of RAGE on the plasmamembrane, since 
the levels of membrane expression seemed to remain constant during the cell cycle. This 
could reflect the different requirement for signaling during different phases or a difference 
in the available ligands for RAGE. We also observed RAGE was regulated by proteolysis, a 
possible additional regulatory mechanism, or a negative feedback loop in RAGE signaling. 
Furthermore studies using 2-DE further show RAGE is posttranslationally modified, most 
likely phosphorylated. We therefore conclude that RAGE signaling is regulated at different 
levels during cell cycle and growth factor withdrawal-induced G1 arrest and consequent 
apoptosis. This stresses the importance of RAGE signaling in the regulation of cell cycle 
and cell death and further emphasizes the complex nature of RAGE signaling. Our 
observations could also partially provide a basis for the dualistic nature role of RAGE 
signaling in proliferation and differentiation, and in survival and the induction of cell death.
MATERIALS AND METHODS
Cell Lines and Cultures 
 The IL-3 dependent pro-B cell line Ba/F3 (61) was purchased from DSMZ. Ba/
F3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with glutamax 
(Invitrogen) supplemented with heat-inactivated FBS (10% v/v) (Cambrex), penicillin (100 
units/ml) and streptomycin (0.1 mg/ml) and 5% conditioned medium from WEHI-3B cells as 
a source of mouse IL-3. Ba/F3 cells were cultured at 37°C in a humidified incubator under 
an 5% CO2 atmosphere.
 Hek293 cells, were cultured in DMEM with glutamax (Invitrogen) supplemented with 
heat-inactivated FBS (10% v/v), penicillin (100 units/ml) and streptomycin (0.1 mg/ml) at 
37°C in a humidified incubator under an 8% CO2 atmosphere.
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Cell stimulations
Ba/F3 cells were synchronized by washing exponentially growing cells 3 times 
in culture medium without conditioned WEHI-3B medium and resuspended in culture 
medium without conditioned WEHI-3B medium for 8 hours or over night. At the end of the 
synchronisation conditioned WEHI-3B medium (5% v/v) was readded. This time point was 
designated 0 hours. 
For IL-3 depletion experiments, IL-3 was removed by washing exponentially 
growing Ba/F3 cells 3 times in culture medium without conditioned WEHI-3B medium and 
resuspended in culture medium without conditioned WEHI-3B medium.
Hek293 cells were depleted by washing them 3 times with culture medium without 
FBS and subsequently cultured in culture medium in the absence of FBS.
Hek293 cells were transiently transfected by Ca-phosphate-precipitation. Vectors 
used are pCAGGS vectors containing full length RAGE (FLRAGE), N-terminally flag tagged 
full length RAGE (N-flag-RAGE), or C-terminally tagged full length RAGE (RAGE-C-flag). 
The vectors were kindly provided by Stefanie Salliau (VIB department of Medical Protein 
Research, Molecular and Metabolic Signaling Unit, Flanders Institute for Biotechnology, 
Faculty of Medicine and Health Sciences, Ghent University).
Chemicals and inhibitors used are nocodazole (0.8 µM; Sigma aaldrich) and Z-VAD-
FMK (promega). Duration and concentrations used as described.
DNA distribution analysis
 Cells were stained with propidium iodide (PI, Sigma) containing staining solution 
(62) and analyzed by a FACSCalibur flow cytometer (488Ex/590Em). Cell Quest software 
was used to analyze cell cycle distribution (FACS Calibur, Becton Dickinson) (62,63). Ten 
thousand cells were routinely analyzed.
Electrophoresis and immunoblotting
 The cells were washed 3 times with ice-cold PBS buffer and lysed with cytosol 
extraction buffer (10 mM Tris-HCl pH7.4, 50 mM EDTA pH8.0, 25 mM NaCl, 0,7% TritonX-
100, 100 mM PMSF, 1 tablet Complete Protease Inhibitor Cocktail (Roche)/50 ml cytosol 
extraction buffer) or modified radioimmune precipitation assay buffer (200 mM NaCl, 50 
mM Tris-HCl (pH 8), 0.05% SDS, 2 mM EDTA, 1% Nonidet P-40, 0.5% deoxycholic acid, 
1 mM Na3VO4,
 1 mM NaF, 20 mM -glycerophosphate, and Complete Protease Inhibitor 
Cocktail). Cell lysates were cleared by centrifugation (14,000 x g). Protein concentrations 
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were determined using Bradford method. Proteins were separated by SDS-PAGE and 
transferred onto a PVDF membrane (Hybond-P, Amersham Pharmacia Biotech). The blots 
were incubated with the desired antibodies followed by ECL-based detection (Amersham 
Pharmacia Biotech). Quantification of protein bands was performed using Genetools 
software (Westburg).
Preparation of cytosolic and nuclear fractions
 Nuclear and cytoplasmic extracts were prepared as previously described with small 
modifications (64). In brief, 10 X 106 Ba/F3 cells were synchronized and after indicated 
time intervals collected. After harvesting and washing the cells 3 times with ice-cold PBS, 
the cells were lysed in 200 µl buffer A (10 mM HEPES, pH 8.0, 1.5 mM MgCl2, 10 mM KCl, 
0.5 mM dithiothreitol, 200 mM sucrose, 1 tablet Complete Protease Inhibitor Cocktail/50 ml 
buffer A, 0.5% NP-40). The lysates were incubated 15 min on ice and pelleted at 11,000 x 
g for 10 min and the cytoplasmic supernatant was transferred to a new tube. The remaining 
nuclear pellets were washed twice with buffer A and resuspended in 150 µL buffer B (20 
mM HEPES, pH 8.0, 20% (vol/vol) glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol, 
1 tablet Complete Protease Inhibitor Cocktail/50 ml, 1% NP-40). These extracts were 
subsequently passed 1 time through a 18 G needle and 3 to 4 times through a 27 G needle 
and centrifuged 30 sec at 14,000 3 g. The pelleted debris was discarded, while the nuclear 
extract and cytosolic supernatants were used for immunoblot analysis. 
2-Dimensional Gel Electrophoresis 
Isoelectric focusing was carried out on 18 cm IPG strips, pH 4-7 (GE Healthcare) 
according to the manufacturer’s instructions. For the second dimension, proteins were 
separated by SDS-polyacrylamide gel electrophoresis (PAGE, 12%).
Surface staining of RAGE
 1X 106 Ba/F3 cells were washed 3 times in ice-cold FACS buffer (PBS, 1% FBS, 0.5 
mM EDTA) and incubated with a polyclonal antibody raised against the N-terminus of RAGE 
(H-300, Santa Cruz Biotechnology) for 20 min. Subsequently cells were washed twice in 
FACS buffer and incubated with a secondary Alexa R488 conjugated anti-rabbit antibody 
(Molecular Probes) for 20 min. Cells were then washed and immediately measured and 
analysed on FACS.
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General conclusions
 The ubiquitous and highly conserved nature of the glyoxalase system suggests a 
fundamental role in life. Indeed, the glyoxalase system has been linked to several cellular 
processes including cell proliferation and growth, the assembly of microtubules and 
vesicle transport (1,2). Still, the glyoxalase is a rather complex enzyme system for merely 
a detoxification reaction. Moreover, several other enzyme systems are also capable of 
detoxifying α-oxoaldehydes. These observations indicate the glyoxalase system may have 
a more profound physiological function. In the 1960s Nobel prize laureate Albert Szent-
Györgyi hypothesized that the glyoxalase system exerts a regulatory role in cell division. 
Ever since then, several investigators reported a strong correlation between high levels of 
expression and high activity of glyoxalase I, and strong cell division. However, the exact 
mechanistic link has yet to be established (3).
 In chapters 6 and 8, we describe a potential involvement of phosphorylated 
glyoxalase I in growth factor-depletion induced G1 arrest and consequent apoptosis, 
and the regulation of the cell cycle. Previous research in our group showed for the first 
time that glyoxalase I can be phosphorylated in mammalian cells (4). Earlier findings in 
yeast by Inoue and his colleagues around 1990 showed that treatment with mating factor 
induces phosphorylation of glyoxalase I and alters glyoxalase I activity (5,6). Mating factors 
induce several responses in yeast, and one thereof is a cell cycle arrest in G1 (7). As 
described in chapter 6, in the hematopoietic cell line Ba/F3 the induction of G1 arrest by 
IL-3 depletion strongly induced multiple phosphorylation of glyoxalase I. Also during the 
cell cycle, glyoxalase was transiently phosphorylated. In the course of our study it was also 
reported that treatment of rice leafs with gibberellin, a regulator of plant growth, induced 
phosphorylation of glyoxalase I (8). Taken together, our data and the observations made 
by others in yeast and rice leafs, strongly suggest either an involvement of phosphorylated 
glyoxalase I in the regulation of the cell cycle or at least the necessity for cells to 
phosphorylate glyoxalase I during the cell cycle. However, the precise biological function 
of phosphorylated glyoxalase I remains to be determined. Although in yeast (5) and plants 
(9) phosphorylation of glyoxalase I has been reported to be accompanied by an increase in 
glyoxalase activity, this does not seem to be the case in mammalian cells ((4) and chapters 
6 and 8). This might be explained in part by the fact that some plants express a novel plant-
specific type of glyoxalase (10,11). As a consequence, our data rule out the possibility 
that, in mammalian cells, phosphorylation of glyoxalase I occurs in order to allow the cells 
to cope with higher levels of methylglyoxal, caused by a cell cycle-dependent increase of 
glycolysis and/or the increased oxidative stress. Together with cell division, growth factors 
dynamically regulate the glycolysis. Growth factor withdrawal on the other hand, leads to a 
decrease in glycolysis. It is therefore conceivable that growth factors link the regulation of 
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the glyoxalase system to the regulation of metabolism.
 
 Studies with kinase inhibitors and in vitro kinase assays revealed the involvement of 
several kinases in pathways leading to the phosphorylation of glyoxalase I. Studies using 
kinase inhibitors showed the involvement of GSK-3β in phosphorylation of glyoxalase I 
upon IL-3 starvation and the involvement of the PI3K/Akt/mTOR pathway in cell cycle 
dependent phosphorylation of glyoxalase I. On the other hand, in vitro studies pointed out 
that CaMKII can directly phosphorylate glyoxalase I. However, unlike inhibition of GSK-3β, 
inhibition of CaMKII, could not inhibit G1 arrest and apoptosis upon IL-3 depletion in Ba/F3 
cells. On the other hand, in other cell signaling pathways, phosphorylation of GLO1 could 
be inhibited by pharmacological inhibition of CaMKII (Rondas et al., in preparation). These 
data indicate that glyoxalase I is a direct physiological target of CaMKII. Interestingly, 
multiple phosphorylations can be induced on glyoxalase I and several kinases and 
signaling pathways have been shown to be involved in the phosphorylation of glyoxalase 
I. It is therefore conceivable that multiple kinases can directly phosphorylate glyoxalase I 
in vivo, or that kinases can substitute for one another in the phosphorylation of glyoxalase 
I, in case the physiological kinase is impaired. Such mechanisms have been described 
e.g. for the phosphorylation of GSK-3β (12,13). Alternatively, several pools of glyoxalase 
I might exist, and different pools might be regulated by various signaling pathways and 
might be involved in different cellular processes. This might explain how phosphorylation 
does not affect the detoxification of methylglyoxal. It might be also possible that depending 
on the site in glyoxalase I that is phosphorylated that effect on the enzyme and thus also 
the biological response can be different.
 Concomitant with the phosphorylation of glyoxalase I, the formation of specific 
methylglyoxal-derived advanced glycation endproducts (MG-AGEs) could be observed. 
Currently we do not know the exact relationship between the phosphorylation of glyoxalase 
I, and the formation of MG-AGEs. One could speculate that formation of MG-AGEs is an 
indirect consequence of a phosphorylation-induced inhibition of glyoxalase I. However, 
this was shown not to be the case. Furthermore, phosphorylation of glyoxalase I could not 
be correlated with alterations in glyoxalase I activity. In yeast and plants, however, where 
phosphorylation was accompanied by an increase in activity of glyoxalase I (5,9).Quite 
interestingly, when phosphorylation of glyoxalase I was inhibited, also formation of specific 
MG-AGEs decreased, similar to the events in TNF-induced necrosis. These observations 
suggest that also in our cell system phosphorylated glyoxalase I and formation of MG-
AGEs are on the same pathway.
 The specific targets for methylglyoxal-modification are currently unknown. Although 
methylglyoxal-modification has been considered to be involved in development of several 
pathologies, such as vascular complications in diabetes, it’s becoming more apparent that 
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methylglyoxal-modification of proteins could be of physiological importance as well (14,15). 
The presence of methylglyoxal is proportional to the rate of glycolytic flux. Since many 
cellular processes and signaling pathways influence glycolysis, methylglyoxal levels and 
methylglyoxal-modification of specific proteins could function as a sentinel for the metabolic 
state of cells. It is tempting to speculate that phosphorylated glyoxalase I is involved in the 
formation of these specific MG-AGEs. 
 Several mechanisms have been described of how MG-modification on proteins 
exerts its effect. Reaction of methylglyoxal with amino acids generates reactive oxygen 
species (16), which can subsequently activate several signaling pathways. Furthermore, 
methylglyoxal has been reported to covalently modify specific residues of several proteins, 
hereby regulating their function (14,15,17,18). Another possibility is through the activation 
of the receptor for advanced glycation endproducts (RAGE). Many signaling pathways 
have been reported to emanate from RAGE (see chapter 3.3). Although RAGE is 
expressed in every cell line studied so far (19), under physiological conditions expression 
levels are low, and RAGE is strongly upregulated under pathological conditions (20). When 
RAGE was studied throughout the cell cycle, we found a strong regulation of the different 
isoforms. These differences could be related to specific cell cycle phases and alterations 
in the expression levels coincided with transitions between phases. In spite of the strong 
regulation of the different isoforms of RAGE, no alteration in expression of RAGE at the 
plasmamembrane was measured. We also discovered a new proteolytic cleaved isoform 
of RAGE, 17 kDa RAGE, which was induced upon IL-3 depletion-induced G1 arrest. We 
therefore hypothesize that RAGE signaling could be involved in proliferation or survival. 
The proteolytic processing of RAGE could thus provide a mechanism for cells to attenuate 
RAGE signaling. Alternatively, the 17 kDa RAGE itself could exert another function in G1 
arrest or the induction of apoptosis.
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